sunday 23 sEpTEMbEr - ehmtic 2012

EHMTIC20I2 

European Headache and Migraine Trust 

International Congress 

ConfErEnCE prograMME 

Hilton London Metropole 

Thursday 20 September – Sunday 23 September 2012 

www.ehmtic2012.com

EHMTIC20I2 



EHMTIC Limited - registered charity no 1121734

EHMTIC20I2 

European Headache and Migraine Trust International Congress 

contents 

■ Welcome Message 5 

■ EHMTIC Board 6 

■ International Scientific 

Advisory Committee 6 

■ Acknowledgements 7 

■ Programme at a Glance 8 

■ Congress Information 10 

■ Social Programme 12 

■ Scheduled Meetings 13 

■ Information for Oral Presenters 14 

■ Information for Poster Presenters 15 

■ Invited Speakers’ Biographies 18 

■ Programme Thursday 20 Sept 24 

■ Programme Friday 21 Sept 27 

■ Programme Saturday 22 Sept 31 

■ Programme Sunday 23 Sept 35 

■ Poster Programme 38 

■ Exhibition Floor Plan 64 

■ List of Sponsors & Exhibitors 65 

■ Directory of Sponsors & Exhibitors 66 

■ Inviter Speaker Abstracts 71 

■ Poster Abstracts 76 

■ Author Index 159

Welcome message 

Welcome to the 3rd European Headache and Migraine Trust International Congress 2012, the premier 

international event for neurologists, physicians, scientists, researchers, and international experts and 

healthcare professionals with an interest in migraine and headache disorders. This year we highlight 

the Year of Headache of the International Association for the Study of Pain with two special lectures 

from absolute world leaders in pain research. 

The four day programme continues to build on its basic and clinical science content by covering the 

latest available research, therapies, and developments from internationally acclaimed leaders in the 

field. The aim of this Congress is to provide a better understanding of migraine, trigeminal autonomic 

cephalalgias and other headache disorders worldwide and to give participants the opportunity to 

gather new scientific evidence and understanding for improving diagnosis and treatment for patients. 

Poster presentations are a key feature of EHMTIC2012 and the programme has been planned to allow 

plenty of time for poster viewing and chaired discussions with an emphasis on interaction across seven 

sessions. We will feature the best of our developing researchers in the New Scientist lectures, an 

opportunity to hear what is happening at the absolute cutting edge. 

Three Teaching Courses scheduled prior to the start of the main programme offer focused updates for 

primary care practitioners and others with a special interest in the field of headache; an educational 

case-based interactive session aimed at clinical staff to update their knowledge and learn about new 

therapies; and a course aimed at trainees interested in novel techniques and developments in migraine 

research. The International Headache Society Primary Care Group and British Association for the Study 

of Headache (BASH) General Practitioners with special interest in headache group has organised a 

session on Saturday afternoon to review the key papers in primary care and to discuss the areas in 

which the primary care research effort should focus including policy guidance for the management of 

headache in schools. 

We will finish with a public session for patients with migraine and headache disorders, providing an 

overview of the Congress presentations. 

The sponsored satellite symposia are also an important part of the programme and we encourage you 

to attend these sessions to learn about the latest developments from our healthcare industry partners. 

On behalf of the International Scientific Advisory Committee, we would like to express our grateful 

thanks to the exhibitors and generous sponsors of the Congress, the EHMTIC Board, The Migraine 

Trust, EHF Board, the abstract reviewers, session chairs, the presenters who are sharing their research 

and experience with us and to our delegates who continue to support the Congress. 

Please take every opportunity within the Congress to learn, familiarise yourself with new ideas and 

hear about the latest study results. Share your knowledge with others, build new friendships and meet 

old acquaintances. We also hope you find time to enjoy the wonderful city of London. 

Yours sincerely, 

Professor Peter J Goadsby and Professor Dominique Valade 

International Scientific Advisory Committee Co-Chairmen 

EHMTIC 2012 

5

6 

EHMTIC20I2 


eHmtIc Board 

Chairperson: Audrey Craven (President, European Headache Alliance (EHA) and President, European 

Federation of Neurological Associations (EFNA)) 

Professor Peter J Goadsby (Trustee, The Migraine Trust) 

Dr Dominic P Valade (President, European Headache Federation) 

Wendy Thomas (Chief Executive, The Migraine Trust) 

Dr Fayyaz Ahmed (Trustee, The Migraine Trust) 

Professor Rigmor H Jensen (1st Vice President, European Headache Federation) 

Company Secretary: Adam Speller (Financial Controller, The Migraine Trust) 

InternatIonal scIentIfIc 

advIsory commIttee 

Dr Simon Akerman (USA) 

Professor Fabio Antonaci (Italy) 

Professor Rami Burstein (USA) 

Professor Andrew Charles (USA) 

Professor David Dodick (USA) 

Professor Peter Goadsby (USA) 

Professor Rigmor H Jensen (Norway) 

Dr Dimos D Mitsikostas (Greece) 

Dr Jes Olesen (Denmark) 

Professor Dr Jean Schoenen (Belgium) 

Professor Lars Stovner (Norway) 

Professor Cristina Tassorelli (Italy) 

Dr Dominique P Valade (France) 

Dr Mark Weatherall (UK)

EHMTIC20I2 


acknoWledgements 

The Organising Committee and EHMTIC Board would like to express their gratitude and kindly acknowledge 

the following companies and organisations for their generous support of the 3rd European Headache and 

Migraine Trust International Congress (EHMTIC2012), organised jointly by The Migraine Trust and the European 

Headache Federation. 

plaTInuM sponsor 

gold sponsor 

sIlvEr sponsor 

ExHIbITors & sponsors 

7

8 

EHMTIC20I2 


Programme at a glance 

09.30–15.30 

Hilton Meeting 

Rooms 1-6 

teaCHing CoURse 

i 

Getting to Grips 

with Headache 

Lunch available 

from 12.40–13.20 

Aimed at 

General 

Practitioners 

THURSDAY 20 SEPT FRIDAY 21 SEPT 

RegistRation fRom 08.00 RegistRation fRom 08.00 

Kings Suite 

12.30–15.30 

Kings Suite 

(Balmoral) 


ii 

How to manage 

migraine! A casebased 

interactive 

session 

Aimed at 

Clinical staff 

15.30–16.00 

BReaK 

12.30–15.30 

Kings Suite 

(Sandringham) 


iii 

Novel techniques 

and developments 

in migraine 

research 

Aimed at 

Basic Scientists 

16.00–17.45 

eHmtiC 2012 oPening CeRemonY anD 

tHe maCDonaLD CRitCHLeY LeCtURe 

The Epidemiology of Migraine Genetics 

Dr Tobias Kurth, University of Bordeaux Segalen, France 

SESSION 1 

17.45–18.15 

BReaK 

18.30–19.30 Kings Suite 

sateLLite sYmPosiUm 

Cluster headache: new data and information... 

Sponsored by Linde Healthcare 

09.00–09.45 

eHmtiC/iasP Joint session 

Relevance of pain imaging studies for understanding migraine 

Professor Irene Tracey, Oxford Centre for FMRI of Brain, UK 

09.45–10.30 

Analgesic drug development: Time to break the mould 

Dr Clifford Woolf, Harvard, USA 

SESSION 2 

10.30–12.00 

PosteR session a 

Genes and Environment: Genetics, Epidemiology and 

Paediatric Headaches 

SESSION 3 

12.00–12.30 

LUnCH BReaK 



BOTOX ® in Chronic Migraine: Sharing Experiences, 

Improving Outcomes 

Sponsored by Allergan 

14.30–16.00 

PosteR session B 

Other Primary Headaches: 

Tension-type headache, 

other TACS and other primary 

headaches 

SESSION 4A 

14.30–16.00 

Hilton Meeting Room A, 

Third Floor 

PaeDiatRiC session 

SESSION 4B 

16.00–16.45 

migRaine tRUst LeCtURe 

Neurobiology of migraine pain 

Dr Karl Messlinger, University of Erlangen-Nürnberg Germany 

SESSION 5 

16.45–17.15 

BReaK 



Single Pulse Transcranial Magnetic Stimulation sTMS: 

A novel, non-invasive, neurostimulation device for acute 

treatment of migraine 

Sponsored by eNeura Therapeutics 

18.45–19.45 

WeLCome ReCePtion & BUffet sUPPeR

EHMTIC20I2 


KeY: ■ COURSES ■ PLENARy SESSIONS ■ SPONSORED SATELLITE SyMPOSIA ■ POSTER SESSIONS 

SATURDAY 22 SEPT SUNDAY 23 SEPT 

07.45-09.00 Windsor Suite 

BReaKfast WoRKsHoP: inteRaCtive inJeCtion WoRKsHoP 

Sponsored by Allergan 


PosteR session C 

Basic Science: Migraine-Basic Experimental Science & Pathophysiology 

SESSION 6 


tHe Jes oLesen eHf LeCtURe 

Headache Research - Where are we heading? 

Dr Rigmor Jensen, Danish Headache Center, Denmark 

SESSION 7 

14.15–15.45 

Kings Suite 

(Sandringham) 

PosteR session D 

Human experimental 

science: 

Migraine – Clinical 

Experimental Science 

and Pathophysiology 

SESSION 9A 

15.45–17.15 

Kings Suite 

(Sandringham) 

PosteR session e 

Headache Care: 

diagnostics and other 

clinical aspects 

of headache 

SESSION 10A 

11.30–12.45 

inviteD neW sCientist LeCtURes 

SESSION 8 

12.45–14.15 

LUnCH BReaK 

14.15–15.45 


Room A, Third Floor 

tHe 

mULtiDisCiPLinaRY 

team 

Rehabilitation of 

Chronic Headache 

SESSION 9B 

15.45–17.15 


Room A, Third Floor 

international 

forum of 

Headache nurses 

SESSION 10B 

14.15–17.15 

The Kings Suite 

(Balmoral) 

inteRnationaL 

HeaDaCHe soCietY 

PRimaRY CaRe 

gRoUP anD BRitisH 

assoCiation 

foR tHe stUDY 

of HeaDaCHe 

(BasH) geneRaL 

PRaCtitioneRs 

WitH sPeCiaL 

inteRest in 

HeaDaCHe gRoUP 

PaRaLLeL session 

Moving the primary 

care agenda 

forward 

SESSION 9C 

17.20–18.10 

enRiCo gRePPi aWaRD 

Depression and risk of transformation of episodic to chronic migraine 

Dr S Ashina, Albert Einstein College of Medicine, USA 

Sponsored by the Italian Society for the Study of Headache 



Triptans: From perception to reality 

Sponsored by The Menarini Group 

19.30–Late Shaka Zulu (by invitation only) 

iHs JUnioR’s foRUm 

RegistRation fRom 08.00 

Kings Suite 

09.00–10.30 

PosteR session f 

Secondary Headaches 

SESSION 11 

10.30–12.00 

PosteR session g 

Pharmacological acute and preventative migraine therapy 

SESSION 12 

12.00–12.40 

tHe giUsePPe naPPi CLUsteR HeaDaCHe aWaRD 

SESSION 13 

12.40–13.00 

aWaRDs PResentation anD eHmtiC CLosing CeRemonY 

eHmtiC PUBLiC PRogRamme 

Room TBC 

12.45–13.30 

Lunch and Registration 

13.30–16.30 

Open to anyone with an interest in migraine and headache, 

including those living with migraine and/or headache disorders 

9

10 

EHMTIC20I2 


congress InformatIon 

daTE 

Thursday 20 to Sunday 23 September 2012 

vEnuE 

Hilton London Metropole 

225 Edgware Road, 

London W2 1JU, UK 

Hotel & Reservations 

Tel: +44 (0)20 7402 4141 

Fax: +44 (0)20 7724 8866 

www.hiltonlondonmet.com 

rEgIsTraTIon 

On-site registration will open on Thursday 20 

September 2012. The registration desk is located in 

the Foyer area of the West Wing on the ground floor. 

The registration desk opening hours are as follows: 

Thursday 20 September 08.00–19.30 

Friday 21 September 08.00–20.00 

Saturday 22 September 08.00–19.30 

Sunday 23 September 08.00–14.00 

ExHIbITIon 

The exhibition is located in the Monarch Suite (First 

and Second Floors of the West Wing). 

The official exhibition opening times are as follows: 





absTraCTs 

All participants will receive a hard copy of the book 

of abstracts and a USB pen containing a soft copy. 

Abstracts can also be viewed on the computers in 

the Internet Café located in the exhibition area of 

the Monarch Suite. The Abstracts of 3rd European 

Headache and Migraine Trust International Congress 

2012 will appear in The Journal of Headache and 

Pain Volume 14 Supplement 1, February 2013. The 

Supplement will be indexed in PubMed, ISI, SCOPUS 

and many other Abstracting & Indexing Institutes. 

The USB pen of the abstracts is kindly sponsored 

by Allergan. 

badgEs 

In the interest of security, all participants and 

exhibitors are requested to wear their name badge 

throughout the Congress to gain access to the lecture 

rooms and exhibition and free use of the cloakroom. 

If you lose your badge, please go to the registration 

desk where you can collect a replacement badge. 

CongrEss bag 

The Congress Bag has been kindly sponsored by MSD. 

CErTIfICaTE of aTTEndanCE 

Certificates of attendance will be available for all 

participants from 12.00 noon on Saturday 22 

September 2012. You will need to have your name 

badge with you in order to collect you certificate of 

attendance. 

CHaIrpErsons and spEakErs 

Please ensure that you are available in your 

presentation room at least 10 minutes before the 

start of the session. It is recommended that all 

Speakers visit the Speaker Preview area to upload their 

presentation to the Congress computers and to discuss 

audio visual requirements, at least two hours prior to 

the start of the session. The Speaker Preview area is 

located in the Presentation Room on the 4th Floor. 

CloakrooM 

A cloakroom facility is available beside the registration 

desk on the Ground Floor of the West Wing. 

CME aCCrEdITaTIon 

The meeting is accredited by the European 

Accreditation Council for Continuing Medical 

Education. For a maximum of, or up to xx European 

CME credits (ECMEC). Each medical specialist should 

claim only those credits that he/she actually spent in 

the educational activity. The EACCME is an institution 

of the European union of Medical Specialists (UEMS), 

www.uems.net. All CME activities approved by the 

EACCME are valid for recognition by the American 

Medical Association (AMA) towards the Physician’s 

Recognition Award (PRA). To convert ECMES’s credit to 

AMA PRA category 1 credit, please contact the AMA.

EHMTIC20I2 


vEnuE Map 

Unless otherwise stated, all poster discussion sessions, plenary sessions and satellite symposia will be held 

in the King’s Suite 

drEss CodE 

Casual business wear. 

gEnEral EnquIrIEs 

For any general enquiries, lost and found items, 

medical assistance etc, please go to the Registration 

Desk where a member of the Conference team will be 

happy to help you. 

InTErnaTIonal sCIEnTIfIC advIsory 

CoMMITTEE/faCulTy 

All members of the International Scientific Advisory 

Committee and faculty can be contacted through the 

registration desk. 

InTErnET aCCEss 

There is a free internet café located in the exhibition 

area and this will be available during the official exhibition 

opening hours. 

languagE 

The official language of the Congress is English. 

lIabIlITy and InsuranCE 

The organisers cannot take any responsibility 

whatsoever for any injury or damage involving 

persons or property during the Congress. Participants 

are advised to take out their own personal, travel 

and health insurance to cover the duration of their 

attendance at the Congress, including travel time. 

lIsT of parTICIpanTs 

A list of participants is displayed on the notice board 

located in the Registration area. 

lunCH and rEfrEsHMEnTs 

Refreshments are available in the exhibition area 

throughout the open hours of the Congress. A buffet 

lunch will be available on Friday and Saturday during 

the official lunch breaks. A take-away lunch will be 

available on Sunday from 12.30 pm. 

MEssagEs 

A message board facility is provided in the registration 

area for exchange of messages. 

MobIlE/CEll pHonEs 

As a courtesy to speakers and other delegates, please 

ensure that all mobile phones and pagers are switched 

off during sessions. 

posTErs 

Posters are located in the Exhibition area. All poster 

discussions will take place in the King’s Suite. 

quEsTIons To spEakErs 

All plenary sessions and poster discussion sessions will 

take place in the Monarch Suite located on the third 

floor of the Tower Wing. Microphones will be in use 

during the discussion periods. Delegates wishing to 

participate in discussions should raise their hand and 

11

12 

EHMTIC20I2 


wait to be acknowledged by the chairman. A member 

of staff will bring a microphone to you so that you can 

ask your question. Once you have asked your question, 

please return the microphone to the steward. 

safETy and sECurITy 

Please do not leave bags or suitcases unattended at 

any time, whether inside or outside the session halls. 

All hotels strongly recommend that you use their safety 

deposit boxes for your valuables when available. 

sECrETarIaT 

The conference secretariat is located at the Registration 

desk throughout the meeting to assist you with any 

questions you may have. 

The Conference Collective Ltd 

114 High Street, Hampton Hill, 

Middlesex TW12 1NT, UK 

Tel +44 (0) 20 8977 7997 

www.conferencecollective.co.uk 

spEakEr prEvIEw rooM 

A speaker preview room is available to download your 

presentation. It will be open at the following times: 





sMokIng 

The Congress hotel is a non-smoking venue. 

soCIal prograMME 

Welcome Reception on Friday 21 September 2012 

A Welcome Reception will be held from 18.45–19.45 

in the Monarch Suite (Exhibition area). Refreshments 

and a buffet supper will be available and the cost is 

included in the registration fee. 

Juniors Forum on Saturday 22 September 2012 

Participation at this event is by invitation only – it will 

take place at Shaka-Zulu, The Stables Market 

Chalk Farm Rd, London NW1 8AB. Coaches will be 

provided to transport participants to and from this 

event. Coaches will leave the Congress Venue at 19.30 

on Saturday 22 September. The event will start at 

20.00 hrs. 

There is no gala dinner at this Congress. 

TransporTaTIon 

The nearest underground station to the Hilton Metropole 

is Edgware Road or alternatively, Paddington which is 

also the nearest main line station and has an express 

train link to Heathrow Airport. Gatwick Airport has a 

direct rail link to Victoria Station. Waterloo International 

Station has an underground link to Hyde Park Corner 

or is fifteen minutes from the hotel by taxi. 

London City Airport is approximately 45 minutes away 

by taxi & Heathrow and Gatwick airports are also 

served by a regular shuttle bus service to hotels in 

Central London. 

The Hilton London Metropole is located outside of 

London’s Congestion Zone and has a secure car park 

with 170 spaces.

EHMTIC20I2 


scHeduled meetIngs 

THursday 20 sEpTEMbEr 2012 

12.30-14.30 I-H-S Advisory Council Hilton Meeting Rooms 7-10 

14.30-16.00 I-H-S Child and Adolescent Committee Hilton Meeting Rooms 7-10 

18.00-20.00 BASH Council Hilton Meeting Rooms 1-6 

frIday 21 sEpTEMbEr 2012 

07.00-09.00 EHMTIC Board Hilton Meeting Rooms 7-8 

12.30-14.00 I-H-S Education Committee Hilton Meeting Rooms 7-8 

16.45-17.45 I-H-S Juniors Committee Hilton Meeting Rooms 7-8 

18.30-20.30 EHF Annual General Meeting Hilton Meeting Rooms 7-10 

saTurday 22 sEpTEMbEr 2012 

07.45-09.00 Cephalagia Board Meeting Hilton Meeting Rooms 7-10 

09.00-10.30 Journal of Headache and Pain, Editorial Board Meeting Hilton Meeting Rooms 5-6(B) 

12.00-13.00 I-H-S Annual General Meeting Hilton Meeting Rooms 1-6 

13.15-14.00 BASH Annual General Meeting Hilton Meeting Rooms 1-6 

sunday 23 sEpTEMbEr 2012 

08.00-09.00 I-H-S Cluster Headache Special Interest Group Hilton Meeting Rooms 7-10 

12.00-22.00 I-H-S Classification Meeting Hilton Meeting Rooms 7-10 

13

14 

EHMTIC20I2 


InformatIon for 

oral Presenters 

The Speaker Preview Room is located in the Presentation Room on the 4th Floor. In order to ensure a smooth 

transition between presenters, use of your own laptop at the lectern is discouraged as this sometimes causes delays 

between presentations. 

The optimal format for slides will be 16:9 (widescreen) using Microsoft PowerPoint 2007/2010. Please note, slides 

created in previous versions of Microsoft PowerPoint, or sized in 4:3 will still be supported. Presenters who wish to 

use their own laptops/ equipment should contact on-site technical staff allowing enough time to check compatibility. 

If using a Powerpoint (or any other computer) presentation, please note you need to bring it on a CD, a DVD or on 

a “disk on key” Memory stick (using the USB port in the computer) and load it on one of the congress computers 

in the Speaker Preview Room, at least 2 hours before the start of the session. You may supply your own laptop 

computer as a back-up. 

Presenters creating slides in Microsoft PowerPoint 2010 will note that any video files (e.g. .wmv, .avi) will be 

embedded within the final presentation file. All presenters with video files, regardless of PowerPoint version, must 

supply the individual video files along with their PowerPoint slides. If combining video films with PowerPoint, please 

make sure to check this with the technical staff and if necessary visit the lecture hall where your lecture is taking 

place, to check the presentation format again. This can be done during the official breaks in sessions, or prior to the 

start of each day. 

IMporTanT noTE for MaCInTosH usErs 

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to 

the instructions below, before bringing it to the Speaker Preview Room: 

■ Use a common font, such as Arial, Times, New Roman, Verdana, etc (special fonts might be changed to a default 

font on a PowerPoint based PC). 

■ Insert pictures as JPG files (and not TIF, PNG or PICT – these images will not be visible on a PowerPoint based PC). 

■ Use a common movie format, such as AVI, MPG and WMV (MOV files from QuickTime will not be visible on a 

PowerPoint based PC). 

You may use your own Macintosh laptop computer as a back-up. In the event that you choose to use this method, 

please check that your laptop has a VGA socket for an external signal. Please bring a laptop to the Speaker Preview 

Room and check that it works correctly in advance of your presentation. Once this has been checked, please ensure 

that you bring your laptop to the session hall where your lecture is taking place during the coffee or lunch break prior 

to your session for a final check. 

Please note that VHS Video Projection, 35 mm slide projection and overhead projection (projection of transparencies) 

will NOT be available.

EHMTIC20I2 



Poster Presenters 

Posters will form an integral part of the Congress programme. Structured poster sessions will take place on 21, 22 

and 23 September 2012. 

Posters are located in the Exhibition area and will be on display for the entire Congress. All poster presenters should 

check their poster number and mount the poster on the correct board. A supply of Velcro to fix your poster will be 

supplied on each board. Further supplies are available from the Faculty Registration desk. 

Poster Presenters are requested to attend their poster for the scheduled time of their poster viewing session. Each 

session will be split between presentation time and discussion time as follows: 

■ first 20 minutes – presenters of even numbered posters will present their poster, odd numbers will be able 

to listen 

■ second 20 minutes – presenters of odd numbered posters will present their poster, even numbers will be able 

to listen 

■ 10 minutes break 

■ 40 minutes discussion in auditorium with selected brief oral presentations. 

Each poster session will be managed by two poster Chairmen who will select a small number of posters for oral 

presentation during the discussion period in each session. Selected poster presenters will have 5 minutes to briefly 

present their poster followed by a general discussion of all the posters in the session. 

prIzEs 

A prize will be awarded for the best poster in each poster session. 

MounTIng and rEMoval of posTErs 

If the poster presenter is unable to meet the set-up or removal times, you must arrange for a co-author or other 

colleague to assist with set-up and/or removal. All posters remaining in the Exhibition Hall after 14.00 hrs on 

Sunday 23 September 2012 will be discarded. 

sToragE of posTEr TubEs and paCkagIng 

A poster tube storage facility is available at the Congress Bag collection point. All poster presenters should ensure 

that their poster tubes are clearly labelled for identification purposes with your name and poster number. 

frIday 21 sEpTEMbEr 

10.30-12.00 

PoSTER SESSIoN A: GENES AND ENvIRoNmENT: GENETIcS, EPIDEmIoloGY AND PAEDIATRIc HEADAcHES 

10.30-11.10 Poster viewing P1-P35, LB02, LB13 – Exhibition area 

11.10-11.20 Break 

11.20-12.00 Poster discussion – Kings Suite 

(selected posters will be presented and discussed) 

Authors of odd numbers (P1, P3, P5, etc) will attend their poster for the first 20 minutes of the poster viewing 

session (10.30-10.50). Authors of even numbered posters (P2, P4, P6,etc) will attend their poster for the second 

20 minutes of the poster viewing session (10.50-11.10). 

15

16 

EHMTIC20I2 



Poster Presenters 

contInued 

14.30-16.00 

PoSTER SESSIoN B: oTHER PRImARY HEADAcHES: TENSIoN-TYPE HEADAcHE AND oTHER TAcS AND 

oTHER PRImARY HEADAcHES 

14.30-15.10 Poster viewing P36-P64, LB07, LB09, LB12, LB14, LB15 – Exhibition area 

15.10-15.20 Break 



Authors of odd numbers (P37, P39, 415, etc) will attend their poster for the first 20 minutes of the poster viewing 

session (14.30-14.50). Authors of even numbered posters (P36, P38, P40,etc) will attend their poster for the 

second 20 minutes of the poster viewing session (14.50-16.10). 

saTurday 22 sEpTEMbEr 

09.15-10.45 

PoSTER SESSIoN c: BASIc ScIENcE: mIGRAINE-BASIc ExPERImENTAl ScIENcE AND PATHoPHYSIoloGY 

09.15-09.55 Poster viewing P65-P96, LB01 – Exhibition area 

09.55-10.05 Break 






14.15-15.45 

PoSTER SESSIoN D: HUmAN ExPERImENTAl ScIENcE: mIGRAINE - clINIcAl ExPERImENTAl ScIENcE 

AND PATHoPHYSIoloGY 

14.15-14.55 Poster viewing P97-P128, LB05, LB08, LB16 – Exhibition area 

14.55-15.05 Break 





second 20 minutes of the poster viewing session (14.35-14.55) 

15.45-17.15 

PoSTER SESSIoN E: HEADAcHE cARE: DIAGNoSTIcS AND oTHER clINIcAl ASPEcTS oF HEADAcHE 


16.25-16.35 Break 



Authors of odd numbers (P131, P133, P135, etc) will attend their poster for the first 20 minutes of the poster 

viewing session (15.45-16.05). Authors of even numbered posters (P130, P132, P134,etc) will attend their poster 

for the second 20 minutes of the poster viewing session (16.05-16.25).

EHMTIC20I2 


sunday 23 sEpTEMbEr 

09.00-10.30 

PoSTER SESSIoN F: SEcoNDARY HEADAcHES 


09.40-09.50 Break 





for the second 20 minutes of the poster viewing session (09.20-09.40). 

10.30-12.00 

PoSTER SESSIoN G: mIGRAINE THERAPY: PHARmAcoloGIcAl AcUTE AND PREvENTATIvE mIGRAINE THERAPY 


11.10-11.20 Break 






17

18 

EHMTIC20I2 


InvIted sPeaker BIograPHIes 

Dr Ishaq Abu-Arafeh 

UK 

Ishaq is a Consultant in Paediatrics and 

Paediatric Neurology at Forth Valley 

Royal Hospital and the Royal Hospital 

for Sick Children, Glasgow, UK and an honorary 

Senior Clinical Lecturer in Child Health, University of 

Dundee. Ishaq qualified from the University of Jordan 

in Medicine in 1980. He had postgraduate training 

in paediatric neurology in Cardiff and Aberdeen. He 

had an MD in migraine and the periodic syndrome in 

children from the University of Aberdeen in 1996. 

For the past 20 years, Ishaq has an active research 

interest in the epidemiology of headache, migraine and 

migraine equivalents and on posttraumatic headache 

in children. He runs the Children’s headache clinic in 

Glasgow for the past 16 years. 

He is the Editor of “Childhood Headache” and 

contributed to several textbooks on paediatrics and 

headache. 

Dr Simon Akerman 

USA 

Dr. Simon Akerman is an Assistant 

Professor in the Headache Research 

Group in the Department of Neurology 

at the University of California, San Francisco, 

California, USA. He received his Ph.D. in Neurological 

sciences at the Institute of Neurology, University 

College London, UK, and his M.Sc. in Neuroscience 

from the Institute of Psychiatry, King’s College London, 

UK. His primary research focus is in understanding the 

pathophysiological mechanisms that underlie primary 

headache disorders to aid the development of better 

therapeutics. This includes understanding the role of 

cannabinoids in trigeminovascular nociception and 

the development of animal models of migraine and 

trigeminal autonomic cephalalgias to help elucidate 

brainstem mechanisms in these disorders. 

Prof Fabio Antonaci 

Italy 

Fabio Antonaci MD, PhD is currently Aggregate 

Professor and Scientific Coordinator at the University 

Consortium for Adaptive Disorders and Headache 

(UCADH), Pavia. He is actually working at the 

Headache Centre, C.Mondino National Institute 

of Neuroplgy Foundation, IRCSS, University of 

Pavia, Italy. Professor Antonaci received his degree 

in medicine at the University of Siena. He then 

specialised in neurology and neurophysiopathology, 

and completed a research fellowship at the University 

of Trondheim in Norway. 

Professor Antonaci is the Editor of EHF News. In 

addition, he is a member of several scientific bodies, 

including the Italian Society of Neurology, the Italian 

Society for the Study of Headache, the European 

Headache Federation, the British Association for the 

Study of Headache and the Swiss Migraine Society. He 

has authored more than 200 publications mainly in the 

fields of headache and autonomic dysfunction, pain 

research and kinematic analysis of neck movement. 

Professor Antonaci has also lectured extensively on 

headache disorders. 

Dr Lars Bendtsen 

Lars Bendtsen, MD, PhD, Dr.Med. 

Sci. is Associate Professor at the 

Department of Neurology and Danish 

Headache Center, Glostrup Hospital, 

University of Copenhagen. 

Dr. Bendtsen received his Ph.D. and Dr.Med.Sci. 

degrees at the University of Copenhagen. He has 

actively been involved in headache research since 

1991 and has authored over 100 papers and book 

chapters on headache topics. Dr. Bendtsen is past 

President of the Danish Headache Society. 

Dr. Bendtsen is co-director of The Danish Headache 

Centre. His main research interest includes clinical 

aspects and treatment of migraine and headache in 

general and more specifically the pathophysiology and 

management of tension-type headache, medication 

overuse headache and trigeminal neuralgia. 

Mrs Audrey Craven 

Ireland 

Audrey Craven is the current President 

of the European Federation of 

Neurological Associations (EFNA). She 

is a founding member and President of the European 

Headache Alliance (EHA). 

Audrey is founder and President of the Migraine 

Association of Ireland (MAI). She is also the former 

Chairperson of the Neurological Alliance of Ireland 

(NAI). She was a member of the Irish neurological 

Expert Advisory Board that produced three Standards of 

Care Documents. 

Audrey sits as the Independent Patient-Chair of the 

European Headache and Migraine Trust International 

Congress (EHMTIC). 

Audrey received a “Fabulous Founders” award for 

volunteering during 2001. Audrey is the 2004 recipient

EHMTIC20I2 


of the international Elizabeth Garrett Anderson 

Award. This prestigious award is given to the 

woman who has done most to alleviate the burden 

of headache worldwide. 

Professor Stefan Evers 

Germany 

Prof Stefan Evers received his 

medical doctoral degree in 1992 at 

the University of Münster, Germany. 

He also holds a doctoral degree in musicology. 

He is working as Head of Department at the 

Neurological Hospital Lindenbrunn and as Professor 

of Neurology at the Department of Neurology, 

University of Münster. He has published more than 

200 scientific papers and several book chapters 

and books on headache and migraine, pain research, 

and general clinical neurology. 

Dr Andreas R Gantenbein 

Switzerland 

Andreas R. Gantenbein is a trained 

neurologist and electrophysiologist 

(electroencepalography, 

electroneuromyography and sleep studies). After his 

basic medical training he worked as a research fellow 

at the Headache Group, Institute of Neurology, NHNN, 

Queen’s Square, London. In 2005 he received his MD 

at the University of Zürich for comparisons of Headache 

Medicine in primary and tertiary care. He was leading 

the Headache Group at University Hospital Zurich before 

he changed to a Leading Position in Neurorehabilitation 

and Pain Medicine at RehaClinic Bad Zurzach. 

He served as a member of the IHS Trainees and 

Residents Committee since 2003 and since 2009 he 

chaired the special interest group. In his chair-period 

the Junior’s Forum and the travel grants programm 

were successfully continued and the T&R poster prices 

have been introduced at the international conferences. 

He is member of staff of the Swiss Headache Society 

and Country Representative in the European Headache 

Federation. 

Dr Charly Gaul 

Germany 

Dr. med. Charly Gaul studied medicine 

at the University of Munich and 

Heidelberg Germany followed by 

fellowship at the University hospital in Erlangen and 

Halle (Salle). He was trained in Neurology, Intensive 

care medicine and Pain medicine. Special interests 

were migraine, cluster headache, headache in children, 

and facial pain. He was research fellow at the University 

of Zürich and head of the Western German Headache 

Center at the University of Essen (Prof. Dr. HC. 

Diener). Since 2012 he is head of the Migraine- and 

Headache Clinic Königstein, Germany. He published 

on multidisciplinary headache treatment, facial pain, 

neurostimulation, and complementary and alternative 

therapies in headache treatment. 

Dr Christian Geber 

Germany 

Dr. C. Geber is a neurologist from 

the University Medical Centre of the 

Johannes Gutenberg-University, Mainz/ 

Germany. His fields of expertise are Quantitative 

Sensory Testing in the context of neuropthic pain 

conditions and pain-associated sensory changes due 

to neural plasticity. He is a member of the German 

network on neuropathic pain (DFNS), the German Pain 

Society (DGS) and the IASP. From 2005 to 2008 he 

was associated to the laboratory of Prof. Dr. R.D. Treede 

(2005–2008), and is currently doing experimental and 

clinical pain studies in the laboratory of Prof. Dr. F. 

Birklein. In 2009, he was awarded the “Pain research 

award” of the German pain society”. 

Professor Kenneth A. Holroyd 

USA 

Kenneth Holroyd, Ph.D. is Distinguished 

Professor Emeritus in clinical and 

health psychology at Ohio University, 

US. He has conducted both laboratory and clinical 

research on chronic headache disorders, including 

clinical trials that evaluate the efficacy of behavioral 

treatments and examine predictors of response to, 

and mechanisms of action of behavioral treatments. 

His publications include over 150 articles and book 

chapters on headache. Dr. Holroyd served as co-director 

of the Headache Treatment & Research Clinics and 

on Panels, NIH Study Sections, Editorial Boards, and 

Boards of Directors. His hobbies include scuba diving 

an acquiring (and drinking) interesting wines. 

Professor Rigmor Højland Jensen 

Denmark 

Professor of Headache and Neurological 

Pain, Danish Headache Center, 

Department of Neurology, Glostrup 

19

20 

EHMTIC20I2 



contInued 

Hospital, University of Copenhagen, Denmark 

Professor Jensen is the Director of The Danish 

Headache Centre in Glostrup, which she co-founded 

in 2001 together with Professor Jes Olesen. In 2010, 

The Danish Headache Center was awarded with Global 

Excellence in Health. Rigmor Højland Jensen is a 

clinical Professor at the University of Copenhagen, 

where she first trained in medicine and neurology. 

Rigmor Højland Jensen is at present, President Elect 

of the European Headache Federation, Director in 

Lifting the Global Burden of Headache and EHMTIC 

and has been the President of the Danish Headache 

Society. Professor Jensen’s research interests include 

epidemiology of headache, pathophysiology of tensiontype 

headache, stroke, medication overuse headache, 

and chronic pain, cluster headache, idiopathic 

intracranial hypertension and CSF regulation. 

Dr Kay Kennis 

UK 

Kay is a part-time salaried GP. She 

qualified from Oxford and undertook 

postgraduate training in medicine at 

Plymouth where she obtained the MRCP, and then at 

The National Hospital for Neurology and Neurosurgery, 

London. She opted for a career in Primary Care and 

was appointed to the GP rotation in Bradford where 

she was awarded the MRCGP, DRCOG and DFFP. She 

joined her current practice in Bradford in 2006. 

In partnership with colleagues from the Neurology 

Department at Bradford she established a Primary 

Care headache service which she manages and which 

receives referrals from the PCT and surrounding 

NHS trusts. In 2010 she was appointed to the NICE 

Guideline Development Group on Headache. 

Dr Tobias Kurth 

France 

Dr. Kurth is a Director of Research 

at the French National Institute of 

Health and Medical Research (Inserm) 

Unit 708 – Neuroepidemiology and the University 

of Bordeaux, Bordeaux, France. He is an Adjunct 

Associated Professor of Epidemiology at the Harvard 

School of Public Health and a member of the Board 

of Trustees of the International Headache Society. 

Dr. Kurth received his M.D. from the University of 

Tübingen in Germany and a doctorate in epidemiology 

from Harvard. His research on migraine focuses 

on the interrelationships with vascular factors and 

cardiovascular disease, genetic determinants, and 

consequences on brain structure and function. Dr. 

Kurth has published >200 research articles and book 

chapters and he is Associate Editor of Cephalalgia and 

Consulting Clinical Epidemiology Editor at the BMJ. 

Professor Anne MacGregor 

UK 

Anne MacGregor is a specialist in 

headaches and women’s health. She 

is Honorary Professor, Centre for 

Neuroscience & Trauma, Blizard Institute of Cell and 

Molecular Science at Barts and the London School 

of Medicine and Dentistry. In addition to her work in 

headache, she works at Barts Sexual Health Centre, 

St Bartholomew’s Hospital and is the CRQ convener 

for the Faculty of Sexual and Reproductive Healthcare. 

Her research crosses the fields of neurology and 

reproductive healthcare, with her MD thesis exploring 

the role of oestrogen in migraine. She has published 

over 150 research papers and book chapters, five 

single author books, four co-authored books and two 

co-edited books. 

Prof Karl Messlinger 

Germany 

Dr med. Karl Messlinger is a Professor 

of Physiology at the Institute of 

Physiology & Pathophysiology of 

the University of Erlangen-Nürnberg, Germany. He 

graduated from the University of Würzburg in Biology 

(1981) and Medicine (1985), received a doctoral 

degree with a study on auditory brainstem responses 

and spent his postdoctoral period in the distinguished 

pain research group of Robert F. Schmidt. 

In 1993 he received the Habilitation degree after 

an extended scientific work about the structure and 

function of nociceptive afferent endings in joint 

tissues. Then he turned to neurohistological and 

neurophysiological studies on meningeal nociception 

in animals with the translational view on the generation 

of headaches. The methods used in his laboratory 

comprise immunohistochemistry, neuronal tracing, 

neuropeptide measurements, extracellular recordings 

from primary afferents and central neurons in vivo 

and in vitro, blood flow measurements and functional 

imaging. 

Professor Messlinger was a research fellow at the 

Dental School of the University of Toronto in 1990 

and a researcher and visiting professor at the Research 

Institute of Environmental Medicine at the University of 

Nagoya, Japan, during several periods between 1995

EHMTIC20I2 


and 2009. As a University Professor he is involved in 

lectures, seminars and practical courses for students 

of Medicine, Dental Medicine, Medical Engineering, 

Pharmaceutics, Psychology, Biology and Informatics. 

He is a member of several scientific communities 

like the Society for Neuroscience, the International 

Association for the Study of Pain and the International 

Headache Society, and he is a co-editor of Experimental 

Brain Research. 

Dr Dimos D. Mitsikostas 

Greece 

Dr Mitsikostas graduated from the 

Aristoteles’ University Medical 

School, Thessaloniki, Greece, in 

1985; five years later he obtained his PhD degree 

in neuropharmacology, from the National University, 

Athens, Greece. He certified in Neurology, in 1993, 

after he fulfilled the 4-year residency in Neurology 

Department, Aeginition Hospital, National University, 

Athens, Greece. He has performed post-doc studies 

in experimental molecular pharmacology of pain at 

the Harvard Medical School, Boston, Massachusetts 

(1996-1998, Professor’s M.A. Moskowitz lab) and 

at the Institute of Neurology, University College 

London, London, UK (Professors’ P.J. Goadsby lab and 

headache clinic). He is member of several national and 

international societies covering the field of neurology, 

headache, multiple sclerosis and pain. He is author 

of 60 peer-reviewed papers with more than 1000 

citations, editor and co-editor in four textbooks and 

reviewer in several international medical journals. He is 

currently vice president of the Executive Board of the 

European Headache Federation. He has been heading 

the Neurology Department of the Athens Naval Hospital 

since 2001. 

Dr Prab Prabhaker 

UK 

Dr Prab Prabhakar is a consultant 

paediatric neurologist at Great Ormond 

Street Hospital NHS Trust and Honorary 

Lecturer in Paediatric Neurology at the University 

College London-Institute of Child Health. He qualified 

from Madras University in Chennai in 1993. He 

undertook General Paediatric and Neurology training in 

the UK and was appointed to this post in 2007. 

He is a general neurologist who sees a wide variety of 

childhood neurological illness including epilepsy, stoke, 

demyelinating disorders, Head Injury –both Accidental 

and Non-Accidental, multidisciplinary assessment of 

complex neurometabolic and genetic conditions across 

the age range. 

He runs the Children’s Headache Services at Great 

Ormond Street. This clinic provides a range of 

comprehensive treatments including in patient care. 

The service has links with Queens square for transition 

of care and international experts. 

He is an executive council member of BASH 

(British Association of Study of Headaches). He is 

the paediatric representative in the classification 

subcommittee of the International Headache Society. 

His research commitment includes, drug trials in 

children for both the acute treatment and prophylaxis 

of migraine. He regularly lectures at the paediatric 

neurology course run by the Institute of Child Health. 

Ronald Allan Purdy, MD, FRCPC, 

FACP, FAHS 

Canada 

R. Allan Purdy MD, FRCPC, is 

Professor of Medicine (Neurology) at 

Dalhousie University. He was Professor and Head of 

the Department of Medicine, and Chief of the Medicine 

Service of the Department of Medicine at Dalhousie 

and Capital Health from 2005 to June of 2011. He is 

a Fellow of the Royal College of Physicians of Canada, 

and was elected a Fellow of the American College of 

Physicians in 2008. He previously was the Professor 

and Head of Neurology at Dalhousie from 1994 to 

2006. 

Dr. Purdy is Past - President of the Canadian Headache 

Society. He is on the editorial boards of Cephalalgia 

and Headache, and is a member of the Education 

Committees of the American Headache Society and 

International Headache Society, and on the Board of 

Directors of both societies. He has directed educations 

courses as a member of the Scientific Program 

Committee of the International Headache Congress 

in Kyoto in 2005, Stockholm in 2007, Philadelphia 

in 2009 and Berlin in 2011 as well as the Migraine 

Trust for many years in London. He has been Chair 

of the Scientific Program Committee of the American 

Headache Society since 2010 and is Co-Chair of the 

Scientific Program for the International Headache 

Society in Boston in 2013. He is an invited speaker 

on migraine and headache disorders worldwide. 

He has received Excellence in Teaching Awards from 

his Department and University on numerous occasions 

as well as an Instructional Leadership Award from the 

Association of Atlantic Universities in Atlantic Canada. 

He is the 2001 recipient of the Award for Outstanding 

Contribution to Continuing Medical Education from 

21

22 

EHMTIC20I2 



contInued 

Dalhousie University, the Achievement Award from the 

Department of Medicine at Dalhousie in 2003, and 

Excellence in Clinical Practice Award from Dalhousie 

Medical School in 2004. Recently he received 

the 2011 Chandler Award from the Department of 

Medicine at Dalhousie for Lifetime Achievement in 

Medical Education. 

He co-authored the Canadian Guidelines for the 

Management of Migraine in Clinical Practice, in the 

CMAJ in 1997/1998. He is involved in clinical trial 

research in migraine and has several papers and 

publications. He is co-editor of Advanced Therapy 

of Headache with the second edition in 2005 and 

coauthor of Headache Pocket Clinician 2010 from 

Cambridge University Press. He is the 2005 recipient 

of the Arnold P. Friedman Distinguished Clinician 

Research Award from the American Headache Society 

for outstanding contribution to the field of headache, 

and the 2007 Life Time Achievement Award from the 

Headache Cooperative of New England. He has been 

named one of the Best Doctors in Canada in 2008. 

He was elected Secretary of the American Headache 

Society in 2010 and elected a Fellow of the American 

Headache Society in 2010. He is the current Treasurer 

of the American Headache Society. 

Dr Marcela Romero-Reyes DDS, 

PhD 

USA 

Dr. Marcela Romero-Reyes is an 

Assistant Professor and the Director 

of the NYU Orofacial and Head Pain Program and the 

Director of the Advanced Program for International 

Dentists in Oral Medicine & Orofacial Pain. 

She is the first recipient of the 2009 AHS/ Migraine 

Research Foundation Thomas E. Heftler Migraine 

Research Award. 

Dr. Romero-Reyes is a graduate from the School 

of Dentistry of the National University of Mexico 

(UNAM). She obtained her PhD and Orofacial Pain 

residency at UCLA and her postdoctoral training at the 

UCLA Headache Research and Treatment Program. 

Dr. Romero-Reyes interests are pain neuro-immuno 

mechanisms and translational models for the study 

of pain and headache. 

Dr Nathalie Roussel 

Belgium 

Nathalie Roussel (PhD, MSc, PT) is 

head of the division of Musculoskeletal 

Physiotherapy at the University College 

of Antwerp, Belgium and post-doctoral researcher 

at the University of Antwerp and Vrije Universiteit 

Brussel. Her research interests include evaluation and 

treatment of patients with chronic musculoskeletal 

disorders, such as chronic low back pain, chronic 

whiplash associated disorders and chronic pelvic pain. 

Her special interests goes to the relationship between 

pain and movement. She has published in several peerreviewed 

journals and was invited at many international 

congresses. 

Dr Guus Schoonman 

Netherlands 

Dr. Guus Schoonman is working at the neurology 

department of the Leiden University Medical Centre. He 

obtained his MD in 2000 and his PhD in 2008 for the 

study of trigger factors in migraine. His main research 

focus is the pathophysiology of migraine in relation 

to the exposure of trigger factors. Since 2001 he has 

served on the trainees and residents subcommittee 

of the IHS and since 2010 he is chairman of the 

education subcommittee and board member of the IHS. 

Dr Till Sprenger 

Switzerland 

Dr. Sprenger trained as a Neurologist in 

Munich/Germany. He has been involved 

in headache and pain research since 

2002 and completed a research fellowship in pain 

management in Munich and later another research 

fellowship in headache in San Francisco. He currently 

holds a research professorship in Basel/Switzerland and 

is Co-Director of the Neurological Outpatient Services 

at the University Hospital in Basel. His research 

interests include functional neuroimaging in headache 

(fMRI and PET) as well as quantitative sensory testing 

(QST) and human experimental models of primary 

headache disorders. 

Professor Christina Tassorelli 

Italy 

MD, PhD, Cristina Tassorelli is an 

Aggregate Professor in Neurology at the 

Department of Neurological Sciences 

of the University of Pavia (I) and co-director of the 

Headache Science Center of the “National Neurological 

Institute C. Mondino” Foundation, Pavia (I). 

She has studied several aspects of headache, spanning 

from basic studies in animal models of pain to clinical 

investigations for understanding pathophysiological

EHMTIC20I2 


mechanisms of headaches and for identifying new 

therapeutic approaches. 

She is currently one of the Directors of the Council 

of the International Headache Society and the Vice- 

President of the European Headache Alliance. 

Professor Çiçek Wöber-Bingöl 

Austria 

Çiçek Wöber-Bingöl was born in 

Ankara, studied constructional 

engineering there and then studied 

medicine at Austria. After graduating in medicine 

from the University of Vienna she trained in neurology 

under the supervision of Prof. Peter Wessely at the 

Department of Neurology. She took keen interest 

and worked in the headache group from the very 

beginning of her professional career. 1990 she was 

invited to join the Department of Child and Adolescent 

Neuropsychiatry where she founded the only universitybased 

outpatient clinic and scientific group for 

headache in children and adolescents in Austria way 

back in 1991 continuing her clinical and scientific 

work in the field of headache in adults. 

She is Professor of Clinical Neurology, is Chairwoman 

of the Child and Adolescent Standing Committee 

of the IHS. She is Adult Neurologist, Psychiatrist, 

Childpsychiatrist and Childneurologist. Her scientific 

work bridges headaches in all age groups focusing on 

classification, diagnosis, trigger factors, comorbidity 

and genetics of migraine. She trains medical students 

and doctors in MUW Vienna, provides educational 

fellowships to researchers coming from different parts 

of the world, is a member of Vienna-open Medical 

Institute. In 2010 she established with a group 

of Turkish doctors the first Society for Headache 

in Children and Adolescents worldwide, with its 

headquarters in Istanbul, Turkey. 

Dr Clifford Woolf 

USA 

Clifford Woolf, MB, BCh, PhD, is 

director of the F. M. Kirby Neurobiology 

Center and the Program in Neurobiology 

at Children’s Hospital Boston in Massachusetts, a 

professor of neurology and neurobiology and member 

of the programs in neuroscience and immunology at 

Harvard Medical School, and a faculty member of the 

Harvard Stem Cell Institute. His pain research focuses 

on understanding basic mechanisms and translating 

the results into new therapeutics and diagnostics. 

He discovered central sensitization and first showed 

that nerve growth factor plays a role in inflammatory 

pain and has published over 300 research papers. His 

current work includes human, mouse, and Drosophila 

genetics, neuroimmunology, molecular neurobiology, 

stem cell biology, and a strategy for silencing pain 

fibers to relieve pain. Dr. Woolf is also a serial 

innovator, holding 15 patents, patent applications, 

and licenses for technological innovations in pain 

management, and he serves as a consultant and 

advisory board member for several biotechnology firms 

and drug companies. He was the first recipient of the 

Distinguished Young Investigator Award of the IASP 

in 1987, recipient of a Distinguished Research Award 

from the American Society for Anesthesia in 2004, 

was a visiting professor at Columbia Medical School 

and was given the Wall Medal from the Royal College 

of Anaesthetists in 2009. More recently, Dr Woolf 

received a Javits Award from the National Institute of 

Neurological Disorders and Stroke of the US National 

Institutes of Health, delivered the Bonica Lecture for 

the International Association for the Study of Pain and 

the Schmidt lecture at MIT. Dr. Woolf is a dedicated 

teacher and mentor and has served on many national 

and international committees on pain research and 

treatment. 

23

24 

EHMTIC20I2 


scIentIfIc Programme 

THursday 20 sEpTEMbEr 

09.30-15.30 

TEaCHIng CoursE I 

HIlton meetIng rooms 1-6 

GETTING TO GRIPS WITH HEADACHE 

Organised by Dr R Jensen (Denmark) and Dr D Kernick (UK) 

The aim of this programme is to provide focused updates for primary care practitioners and others with a special 

interest in the field of headache. The course is delivered by a mixture of general practitioners with a special 

interest in headache and headache specialists. 

09.30 – 09.40 Impact of headache, what is happening in primary care? 

D. Kernick, UK 

09.40 – 10.10 Optimising the 10 minute headache consultation 

R Jensen, Denmark 

10.10 – 10.40 To scan or not to scan? 

(All UK GPs will have direct MRI access from 2012) 

Who should be scanned? What might you find? 

Questions 

10.40 – 10.50 BREAK 

10.50 – 11.20 

Treating primary headaches 

Management of migraine 

D Mitsikostas, Greece 

11.20 – 11.35 Tension type headache 

L Bendtsen, Denmark 

11.35 – 11.50 Cluster headache 

F Antonaci, Italy 

11.50 – 12.40 Brief updates I 

Secondary headaches and facial neuralgias: medication overuse headache, temporal arteritis 

and high/low pressure headaches 

R Jensen, Denmark and F Antonaci, Italy 

12.40 – 13.20 LUNCH 

13.20 – 13.50 Headache in children 

P Prabhaker, UK 

13.50 – 14.20 National Institute for Health and Clinical Excellence (NICE) 

Headache Guidelines 

K Kennis, UK 

14.20 – 15.10 Brief updates II 

Menstrual migraine, migraine and contraception, migraine and pregnancy and 

migraine triggers 

A McGregor, UK 

15.10 – 15.30 PANEL qUESTIONS AND CLOSE

EHMTIC20I2 


12.30-15.30 TEaCHIng CoursE II 

kIngs suIte (Balmoral) 

HOW TO MANAGE MIGRAINE! A CASE-BASED INTERACTIVE SESSION 

Organised by Dr A Purdy (Canada) 

A fun and educational case-based interactive session aimed at clinical staff 

12.30 Overview and Case Presentations 

A Purdy, Canada 

15.30 CLOSE 

Managing Low Frequency Episodic Migraine 

A Cohen, UK 

Managing High Frequency Episodic Migraine 

G Schoonman, Netherlands 

Managing Chronic Migraine 

A Gantenbein, Switzerland 

Concluding Remarks 

A Purdy, Canada 

12.30-15.30 TEaCHIng CoursE III 

kIngs suIte (sandrIngHam) 

NOVEL TECHNIqUES AND DEVELOPMENTS IN MIGRAINE RESEARCH 

Organised by Dr S Akerman (USA) and Dr T Sprenger (Switzerland) 

12.30 Introduction and Pathophysiology of Migraine 

S Akerman, USA 

15.30 CLOSE 

Basic sciences 

Cortical neurovascular uncoupling – impact in migraine 

P Holland, Scotland 

Translational behavioural sensory testing in rodent models of headache 

M Romero-Reyes, USA 

Clinical Sciences 

Investigating cortical function in headache patients with functional imaging – 

a network perspective 

T Sprenger, Switzerland 

Allodynia and sensory testing in the context of human experimental pain models: 

relation to headache 

C Geber, Germany 

25

26 

EHMTIC20I2 



contInued 

16.00-17.45 EHMTIC 2012 opEnIng CErEMony and 

THE MaCdonald CrITCHlEy lECTurE 

SESSION 1 

17.45-18.15 BREAK 

Chairpersons: PJ Goadsby, USA, D Valade, France 

The Epidemiology of Migraine Genetics 

Recent Findings, Implications, and Future Directions 

Dr Tobias Kurth MD, ScD 

University of Bordeaux Segalen, France 

18.30-19.30 saTEllITE syMposIuM 

CLUSTER HEADACHE: NEW DATA AND INFORMATION... 

Chairperson: Prof. Dr. Rigmor Jensen (Denmark) 

Sponsored by Linde Healthcare 

18.30-18.45 

The use of oxygen administered by three different types of face mask to treat acute attacks 

of cluster headaches: A blinded, randomised, crossover study 

Prof. Dr. Rigmor Jensen (Denmark) 

18.45-19.00 Observational and prospective pilot study assessing the economic cost for one month of 

patients with cluster headache 

Prof. Dr. Dominique Valade (France) 

19.00-19.15 Cluster headache in Europe : preliminary results 

Dr. Colette Andree (Switzerland) 

19.15-19.30 Influence of oxygen inhalation using a demand valve and breathing techniques in a human 

experimental model of trigemino – vascular pain 

Prof. Dr. Arne May (Germany)

EHMTIC20I2 



EHMTIC/Iasp JoInT sEssIon 

SESSION 2 

Chairpersons: R Burstein (USA), D Mitsikostas (Greece) 

09.00-09.45 Relevance of Pain Imaging Studies for Understanding Migraine 

I Tracey 

Nuffield Professor, Anaesthetic Science and Director, Oxford Centre for FMRI of Brain, UK 

09.45-10.30 Analgesic drug development: Time to break the mould 

C Woolf, MB, BCh, PhD 

F.M. Kirby Neurobiology Center, Boston Children’s Hospital and Department of Neurobiology, 

Harvard Medical School, Boston MA, USA 

10.30-12.00 posTEr sEssIon a 

SESSION 3 

Genes and Environment: Genetics, Epidemiology and Paediatric Headaches 

Chairpersons: G Terwindt (Netherlands), V Guidetti (Italy), Z Katsarava (Germany) 

Poster numbers P1-P35, LB02, LB13 

including ongoing refreshments 

10.30-11.10 Poster viewing in Exhibition Area 

11.10-11.20 BREAK 

12.00-12.30 LUNCH BREAK 

11.20-12.00 Poster discussion in Kings Suite 


BOTOX ® IN CHRONIC MIGRAINE: SHARING EXPERIENCES, IMPROVING OUTCOMES 

Chairperson: Hans-Christoph Diener (Germany) 

Sponsored by Allergan Inc 

12.30-12.40 Welcome and introduction 

Chairman: Hans-Christoph Diener (Germany) 

12.40-13.05 From guidelines to clinical practice: identification and diagnosis of the chronic 

migraine patience 

Hans-Christoph Diener (Germany) 

13.05-13.35 Cost-effectiveness of BOTOX ® in chronic migraine: real-life experience 

John Rothrock (USA) 

13.35-14.05 Managing the chronic migraine patient on BOTOX ® : lessons from clinical practice 

Reto Agosti (Switzerland) 

14.05-14.25 Panel discussion 

27

28 

EHMTIC20I2 



contInued 

14.25 Summary 

Hans-Christoph Diener (Germany) 

14.30 CLOSE 

14.30-16.00 posTEr sEssIon b 

SESSION 4A 

Other Primary Headaches: Tension-type headache, other TACS and other primary headaches 

Chairpersons: L Bendtsen (Denmark) and D Magis (Belgium) 

Poster numbers P36-P64, LB07, LB09, LB12, LB14, LB15 



15.10-15.20 BREAK 


14.30-16.00 paEdIaTrIC sEssIon (HIltON MEEtINg ROOM A, tHIRd FlOOR) 

SESSION 4b 

Organised and chaired by: C.Wöber-Bingöl and I. Abu-Arafeh 

14.30-14.50 Epidemiology and Burden of Headache in Children and Adolescents 

Dr I. Abu-Arafeh, Stirling Community Hospital and Royal Hospital for Sick Children, UK 

14.50-15.10 Therapeutic Strategies 

Dr P. Prabhakar, Great Ormond Street Hospital, UK 

15.10-15.30 Clinical Features and Comorbidity of Headache in Children and Adolescents 

Ç .Wöber-Bingöl, Medical University of Vienna, Austria 

15.30-15.50 Study Design Strategies for working with Headache in Children and Adolescents 

Prof S Evers, University of Münster, Germany 

15.50-16.00 questions 

16.00-16.45 MIgraInE TrusT lECTurE 

SESSION 5 

16.45-17.15 BREAK 

Chairpersons: L Stovner (Norway), M Weatherall (UK) 

Neurobiology of Migraine pain 

K Messlinger 

University of Erlangen-Nürnberg, Germany

EHMTIC20I2 


29

30 

EHMTIC20I2 



contInued 


SINGLE PULSE TRANSCRANIAL MAGNETIC STIMULATION STMS: 

A NOVEL, NON-INVASIVE, NEUROSTIMULATION DEVICE FOR ACUTE 

TREATMENT OF MIGRAINE 

Sponsored by eNeura Therapeutics 

Welcome and Introduction: Programme Overview 

Chairman: Professor Peter J. Goadsby, MD, PhD, FRACP FRCP 

Neurostimulation in Neurology: Its future in headache disorders including Migraine 

Fayyaz Ahmed, MD, FRCP, MBA, MRCP (Neuro) 

Transcranial Magnetic Stimulation: Scientific and Safety Review 

Kevin G. Shields MD, PhD, MRCPI 

Transcranial Magnetic Stimulation: Underlying Mechanisms of Action in Treatment 

of Acute Migraine 

Anna Andreou, PhD 

SpringTMST for Treatment of Acute Migraine: UK Post Market Pilot Programme Results 

Mark W Weatherall, PhD FRCP Edin 

Closing Remarks and q&A 

Peter J. Goadsby, MD, PhD, FRACP FRCP 

18.45-19.45 wElCoME rECEpTIon and buffET suppEr

EHMTIC20I2 



07.45-09.00 brEakfasT worksHop (WINdSOR SuItE) 

INTERACTIVE INJECTION WORKSHOP 

Sponsored by Allergan Inc 

09.15-10.45 posTEr sEssIon C 

SESSION 6 

Basic Science: Migraine-Basic Experimental Science and Pathophysiology 

Chairpersons: S Akerman (USA), A Maasen van Den Brink (Netherlands) 

Poster numbers P65-P96, LB01 



09.40-09.50 BREAK 


10.45-11.30 THE JEs olEsEn EHf lECTurE 

SESSION 7 

Chairpersons: D Dodick (USA), C Tassorelli (Italy) 

Headache Research – Where are we heading? 

R Jensen 

Professor of Headache and Neurological Pain, Danish Headache Center, Denmark 

11.30-12.45 InvITEd nEw sCIEnTIsT lECTurEs 

SESSION 8 

8.1 Effects of glyceryl trinitrate and calcitonin-gene-related peptide on BOLD signal and arterial 

diameter – methodological studies by fMRI and MRA 

Asghar, M.S.; Ashina, M. 

Danish Headache Center, Denmark 

8.2 A multidisciplinary approach to the functional abnormalities of the migrainous brain and 

non-invasive interventions to treat them 

Alessandro Viganò1,2,3 ; Volodymyr B Bogdanov4 ; Jean Schoenen1,5 1 5 Headache Research Unit, Dept of Neurology & Giga-Neurosciences, University of Liège, 

Belgium. 2Brain Morphometry and Dynamics Lab., Dept of Anatomy, Histology, Forensic 

Medicine and Orthopaedics, Sapienza University of Rome, Italy. 3Neurology A. Dept of 

Neurology and Psychiatry, Sapienza University of Rome, Italy. 4Department of Neurology, 

University of Utah, Salt Lake City, USA 

SESSION cONtINuES � 

31

32 

EHMTIC20I2 



contInued 

8.3 Cortical modulation of thalamic function during cortical spreading depression – 

Unraveling a new central mechanism involved in migraine aura 

Anna P Andreou1,2 ; Till Sprenger1,3 ; Peter J Goadsby1 1Headache Group - Department of Neurology, University of California, San Francisco, San 

Francisco, CA, United States. 2Anesthetics, Pain Medicine and Intensive Care Section, 

Division of Medicine, Imperial College London, London, UK. 3Department of Neurology and 

Division of Neuroradiology, University Hospital Basel, Basel, Switzerland 

12.45-14.15 LUNCH 

14.15-15.45 posTEr sEssIon C 

SESSION 9A 

Human experimental science: Migraine- Clinical Experimental Science and Pathophysiology 

Chairpersons: T Springer (Switzerland), J Moeller-Hansen (Denmark) 

Poster numbers P97-P128, LB05, LB08, LB16 



14.55-15.05 BREAK 


14.15-15.45 THE MulTIdIsCIplInary TEaM (HIltON MEEtINg ROOM A, tHIRd FlOOR) 

SESSION 9A 

REHABILITATION OF CHRONIC HEADACHE 

THE MULTIDISCIPLINARY TEAM APPROACH TO TREATMENT 

Organised by Dr R Jensen and Professor C Tassorelli 


R Jensen, Denmark 

14.20-14.35 Efficacy of multidisciplinary rehabilitation of patients with chronic headache 

Charly Gaul, Frankfurt, Germany 

14.35-14.50 Management of chronic sensitization, from drugs to physical therapy 

Nathalie Roussel, Belgium 

14.50-15.05 Psychological management in Chronic headache 

Ken Holroyd, USA 

15.05-15.20 The role of electronic aids in the outcome of MOH 

Cristina Tassorelli, Italy 

15.20-15.35 Cost-effectiveness of the multimodal approaches to Chronic Headache 

Rigmor Jensen, Denmark 

15.35-15.45 Discussion

EHMTIC20I2 


14.15-17.15 InTErnaTIonal HEadaCHE soCIETy prIMary CarE group and 

brITIsH assoCIaTIon for THE sTudy of HEadaCHE (basH) gEnEral 

praCTITIonErs wITH spECIal InTErEsT In HEadaCHE group 

parallEl sEssIon (tHE KINgS SuItE, bAlMORAl) 

SESSION 9c 

MOVING THE PRIMARY CARE AGENDA FORWARD 

Organised by Dr David Kernick, UK 

Aimed at GPs with a special interest in headache 

This session will be run by the IHS Primary Care Group and the British Association for the 

Study of Headache General Practitioner with a Special Interest Group. 

14.15 – 14.45 Headache research in primary care – where are we and where are the gaps? 

(A review of the key papers in primary care and a discussion of the areas in which the 

primary care research effort should focus.) 

14.45 – 15.15 What do General Practitioners with a Special Interest in Headache image and what do 

they find? 

Dr Steve Elliott 

15.15 – 15.30 BREAK 

15.30 – 16.00 Reflections on National Institute of Health and Clinic Excellence (NICE) headache guidelines 

Dr Kay Kennis 

16.00 – 16.25 Improving the management of headache in schools 

Dr David Kernick 

This will focus around a programme of primary care led research which has informed the 

Royal College of General Practitioners/Royal College of Nursing policy guidance for the 

management of headache in schools. 

16.25 – 16.50 Delivering headache care from General Practitioners with a special interest – 

where is the evidence? 

Dr Leone Ridsdale 

16.50 – 17.15 Preventive treatment for migraine in primary care, a population based study in the 

Netherlands 

Dr Frans Dekker 

15.45-17.15 posTEr sEssIon E 

SESSION 10A Headache Care: diagnostics and other clinical aspects of headache 

Chairpersons: M Linde (Norway), M Alena (Italy) 

Poster numbers P130-P147, LB04 



16.25-16.45 BREAK 


33

34 

EHMTIC20I2 



contInued 

15.45-17.15 InTErnaTIonal foruM of HEadaCHE nursEs (HIltON MEEtINg ROOM A, tHIRd FlOOR) 

SESSION 10b Organised by Annette Vangaa Rasmussen (Denmark), Jill Murphy (UK) and Esther Thomkins 

(Ireland) on behalf of the International Forum for Headache Nurses 

Aimed at Specialist Nurses in Headache Care 

15.45-15.50 Welcome 

A Vangaa Rasmussen, Nurse Specialist, Danish Headache Centre, Denmark 

15.50-16.00 Nurses role in Headache Care – Presentation of results of survey carried out survey within 

the field of Headache Nursing world-wide 

A Vangaa Rasmussen, Nurse Specialist, Denmark 

16.00-16.15 The Nurses’ role at the Headache Centre in York, UK 

J Murphy, Nurse Specialist, UK 

16.15-16.25 Development within nursing – Award winning information board 

E Thomkins, Nurse Specialist, Ireland 

16.25-16.40 The Nurses’ Role at the Danish Headache Centre 

A Fjelborg Jonasson, Nurse Specialist, Denmark 

16.40-16.55 Management of medication overuse headache 

S Munksgaard, MD, PhD Student, Danish Headache Centre, Denmark 

16.55-17.15 Presentation and approval of the constitution for the “International Forum for Headache 

Nurses” including election of Chairman, Secretary and Treasurer 

17.20-18.10 EnrICo grEppI award 

Depression and risk of transformation of episodic to chronic migraine 

Dr S Ashina, Beth Israel Medical Centre, Albert Einstein College of Medicine, USA 

Sponsored by Italian Society for the Study of Headache 


TRIPTANS: FROM PERCEPTION TO REALITY 

Chairpersons: M.D. Ferrari, S. Evers 

Sponsored by The Menarini Group 

18.15 Introduction 

M. D. Ferrari (The Netherlands) 

18.20 Migraine in menstruating women: what is so special? 

A. MacGregor (UK) 

18.35 Interactive session: Optimizing triptan therapy 

M.D. Ferrari (The Netherlands), C. Lisotto (Italy) 

19.05 Conclusions 

S. Evers (Germany) 

19.30-laTE JunIor’s foruM 

A social event open to Junior Members of the International Headache Society – by invitation only.

EHMTIC20I2 



from 08.00 REGISTRATION 

09.00-10.30 posTEr sEssIon f 

SESSION 11 

Secondary Headaches 

Chairpersons: D Mitsikostas (Greece), J Trajkovic (Serbia) 



09.00-09.40 Poster viewing 

09.40-09.50 BREAK 

09.50-10.30 Poster discussion 

10.30-12.00 posTEr sEssIon g 

SESSION 12 

Pharmacological acute and preventative migraine therapy 

Chairpersons: M Ashina (Denmark), J Hoffman (Germany) 



10.30-11.10 Poster viewing 

11.10-11.20 BREAK 

11.20-12.00 Poster discussion 

12.00-12.40 THE gIusEppE nappI ClusTEr HEadaCHE award 

SESSION 13 

Chairpersons: F Antonaci (Italy), J Schoenen (Belgium) 

12.40-13.00 awards prEsEnTaTIon and EHMTIC ClosIng CErEMony 

Chairpersons: PJ Goadsby (USA), R Jensen (Denmark) 

35

36 

EHMTIC20I2 


PuBlIc Programme 


12.45-16.30 EHMTIC publIC prograMME 

On the final day of the European Headache and Migraine Trust International Congress (EHMTIC) the public are 

invited to an afternoon session to learn about the latest research and treatment for migraine. 

The EHMTIC 2012 Public Session on Sunday 23rd September offers a rare opportunity to hear about latest 

migraine research as EHMTIC takes place in the UK just once every four years. Taking place in central London 

from 12.45pm-4.30pm, the public session will feature presentations by experts in the field of migraine and 

headache. The event begins with a welcome lunch, offering an opportunity to meet other migraine sufferers. 

The EHMTIC public session is open to anyone with an interest in migraine and headache, including those living 

with migraine and/or headache disorders. 

12.45-13.30 REGISTRATION AND LUNCH 


Chairpersons: 

Audrey Craven 

Chair of EHMTIC (European Headache and Migraine Trust International Congress) Board, 

President of EHA (European Headache Alliance) and President of EFNA (European 

Federation of Neurological Associations) 

Wendy Thomas 

Chief Executive of The Migraine Trust, Director of EHMTIC and Treasurer of IHS 

(International Headache Society) 

13.35-14.10 Migraine and depression research 

Dr Tobias Kurth MD, ScD 

University of Bordeaux, France 

14.10-14.45 Launch of NICE (National Institute for Clinical Excellence) Headache Guidelines 

Dr Kay Kennis 

GP with a Special Interest in Headache, Bradford and Airedale, UK 

14.45-14.55 Patient case study 

Patient experience - BOTOX ® 

Elaine Ransome 

14.55-15.15 TEA AND COFFEE 

15.15-15.50 Sleep and Migraine Research 

Dr Alex Nesbitt 

Research Fellow, Surrey Sleep Research Centre, University of Surrey, UK 

Congress research round-up and q&A 

Professor Peter J Goadsby 

Co-Chair of EHMTIC, Trustee of The Migraine Trust, Professor of Neurology at the University 

of California, San Francisco (UCSF) and Director of the UCSF Headache Center, USA 

16.25-16.30 Close of public programme 

Audrey Craven and Wendy Thomas 

Places must be booked in advance. There is a nominal charge of £10 per person to attend or £8 for concessions 

(Student/Disability Living Allowance/Job Seekers Allowance/etc). Places can be booked online via Eventbrite – 

see ‘Ticket Information’ below. 

If you have questions about this event or would prefer to book your place(s) by phone please contact The Migraine 

Trust on 020 7631 6977 or email events@migrainetrust.org

EHMTIC20I2 


37

38 

EHMTIC20I2 


Poster Programme 

Posters will form an integral part of the Congress programme. Structured poster sessions will take place on 

21, 22 and 23 September 2012 as follows: 


10.30-12.00 

posTEr sEssIon a: 

gEnEs and EnvIronMEnT: gEnETICs, EpIdEMIology and paEdIaTrIC HEadaCHEs 


11.10-11.20 Break 




session (10.30-10.50). Authors of even numbered posters (P2, P4, P6,etc) will attend their poster for the second 

20 minutes of the poster viewing session (10.50-11.10). 

PoSTER PRESENTATIoNS 

P1 A rare case of persistent visual aura in a 12 year old girl 

Prabhakar, P.; Simpson, J.C. 

Great Ormond Street Hospital, United Kingdom 

P2 London 2012 – A survey of the impact of headache on UK elite athletes 

Hall, R.; Reddin, L.; Weatherby, S. 

Peninsula Headache Clinic, United Kingdom 

P3 The prevalence of primary headache and its association with socioeconomic factors among school children 

in Lithuania 

Januskeviciene, A.; Zaborskis, A.; Vaitkaitiene, E. 

Lithuanian University of Health Science, Lithuania 

Januskeviciene A., Zaborskis A., Vaitkaitiene E. Institute for Biomedical Research of Kaunas University of Health Science , 4, 

Eiveniu str., Kaunas, LT-50009, Lithuania 

P4 The clincal characteristics of abdominal migraine and risk factors for developing migraine later in childhood 

Lee, K.H.; Kim, E.Y.; Lee, J.H.; Kim, S.K. 

Department of Pediatrics Kangnam Sacred Heart Hospital, Hallym University Medical Center, Korea, 

P5 Frequency and pattern of migraine among medical and nursing students at Enugu, South East Nigeria 

Ezeala-Adikai, B.A. 1 ; Ekenze, O.S. 2 ; Onwuekwe, I.O. 3 

1University of Nigeria Teaching Hospital, Enugu, Nigeria; 2University Of Nogeria Teaching Hospital Enugu, Nigeria; 3University of 

Nigeria Teaching Hospital, Nigeria 

P6 The effect of sleep duration in clinical features and impact of migraine: Result from a population-based study 

Kim, B.K. 1 ; Kim, J.M. 2 ; Lee, K.S. 3 ; Chu, M.K. 4 

1 2 Department of Neurology, Eulji University School of Medicine, Korea, Republic of; Department of Neurology, Chungnam National 

University, College of Medicine, Korea, Republic of; 3Department of Neurology, Seoul St.Mary’s Hospital, The Catholic University of 

Korea, Korea, Republic of; 4Department of Neurology, Hallym University College of Medicine, Korea, Republic of

EHMTIC20I2 


P7 Excessive daytime sleepiness and migraine: A population-based study 

Kim, B.K. 1 ; Kim, J.M. 2 ; Lee, K.S. 3 ; Chu, M.K. 4 

1 Department of Neurology, Eulji University School of Medicine, Korea, Republic of; 2 Department of Neurology, Chungnam National 

University, College of Medicine, Korea, Republic of; 3 Department of Neurology, Seoul St.Mary’s Hospital, The Catholic University of 

Korea, Korea, Republic of; 4 Department of Neurology, Hallym University College of Medicine, Korea, Republic of 

P8 Adolescents with chronic headaches- mental health problems and coping patterns 

Hartberg, S. 1 ; Lundqvist, C. 2 ; Clench-Aas, J. 3 ; Raanaas, R.K. 1 

1 Norwegian University of Life Sciences, Norway; 2 HØKH, Research Centre, Akershus University Hospital, Norway; 3 Norwegian 

Institute of Public Health, Norway 

P9 Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention 

(AMPP) study 

Manack, A.N. 1 ; Serrano, D. 2 ; Turkel, C.C. 3 ; Lipton, R.B. 4 ; Buse, D.C. 4 

1 2 3 Allergan, Inc., Irvine, California, United States; Vedanta Research, Chapel Hill, North Carolina, United States; Allergan, Inc, 

United States; 4Department of Neurology, Albert Einstein College of Medicine and the Montefiore Headache Center, Bronx, New 

York, United Kingdom 

P10 Cerebral venous hemodynamic disturbances in children with different types of headache. The role of 

transcranial ultrasonography methods 

Abramova, M.F.; Stepanova, I.A.; Novoselova, S.N. 

Russian National Research, Medical University Named After N.I. Pirogov, Russian Federation Marina Abramova, Irina Stepanova, 

Svetlana Novoselova. 

P11 Unraveling migraine susceptibility in females: The involvement of GABA genes 

quintas, M.S. 1 ; Neto, J.L. 1 ; Pereira-Monteiro, J. 1 ; Barros, J. 2 ; Sequeiros, J. 1 ; Sousa, A. 1 ; Alonso, I. 1 ; Lemos, C. 1 

1 2 IBMC, Portugal; ICBAS, Portugal 

P12 The relationship between headache and chronic musculoskeletal complaints: An 11-year follow-up in 

The Nord-Trøndelag Health Study (HUNT) 

Stovner, L.J. 1 ; Hagen, K. 2 ; Linde, M. 2 ; Steiner, T.J. 1 ; Zwart, J.A. 3 

1 2 Department of Neuroscience, Norwegian university of Science and Technology, United Kingdom; Department of Neuroscience, 

Norwegian university of Science and Technology, Norway; 3Oslo University Hospital, Norway 

P13 Risk factors for MOH and chronic daily headache: an 11-year follow-up study. The Nord-Trøndelag Health 

Studies (HUNT). 

Hagen, K. 1 ; Linde, M. 1 ; Steiner, T.J. 2 ; Zwart, J.A. 3 ; Stovner, L.J. 1 

1 2 Department of Neuroscience, Norwegian University of Science and Technology, Norway; Department of Neuroscience, Norwegian 

University of Science and Technology, United Kingdom; 3Oslo university Hospital, Norway 

P14 Developmental coordination disorder and migraine in childhood 

Esposito, M. 1 ; Faraldo, M.A. 2 ; Antinolfi, L. 2 ; Carotenuto, M. 2 

1 2 Department of Child and Adolescent Neuropsychiatry, Italy; Department of Child and Adolescent Neuropsychiatry, Italy 

P15 Nutraceutical preparations in childhood migraine prophylaxis 

Carotenuto, M.; Antinolfi, L.; Faraldo, M.A.; Di Dona, A.; Esposito, M. 

Department of Child and Adolescent Neuropsychiatry, Italy 

P16 BDNF gene polymorphysm RS2049046 in episodic and chronic migraine 

Azimova, Y.; Sergeev, A.; Skorobogatykh, K. 

1st Moscow State Medical University, Russian Federation 

39

40 

EHMTIC20I2 



contInued 

P17 Altered pain perception in children with chronic tension-type headache 

Soe, A.L. 1 ; Thomsen, L.L. 2 ; Tornoe, B.1; Skov, L. 3 

1 Children´s Headache Clinic, Department of Paediatrics, Herlev University Hospital, Copenhagen, Denmark; 2 Department of 

Neuropaediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 3 Department of Paediatrics, Herlev 

University Hospital, Copenhagen, Denmark 

P18 Association of lower level of leisure-related physical activity with primary headaches 

Ashina, S. 1 , Bendtsen, L. 2 ; Lyngberg, A.C. 3 ; Lipton, R.B. 4 ; Hajiyeva, N. 5 ; Jensen, R. 6 

1 Medicine, Palliative Care, Neurology, Albert Einstein College of Medicine, Beth Israel Medical Center, United States; 2 Danish 

Headache Center, Neurology, University of Copenhagen, Glostrup Hospital, Denmark; 3 National Board of Health, Copenhagen, 

Denmark; 4 Neurology, Albert Einstein College of Medicine, Montefiore Headache Center, United States; 5 Pain Medicine and 

Palliative Care, Albert Einstein College of Medicine, Beth Israel Medical Center, United States; 6 Danish Headache Center, 

Neurology, University of Copenhagen, Glostrup Hospital, Denmark 

P19 Novel SCN1A mutation in the IFMT motif of the α1 subunit of the voltage-gated NaV1.1 channel causing 

familial hemiplegic migraine 

De Vries, B. 1 ; Weller, C.M. 1 ; De Fàbregues, O. 2 ; Koelewijn, S.C. 1 ; Stam, A.H. 3 ; Haan, J. 3 ; Ferrari, M.D. 3 ; 

Terwindt, G.M. 3 ; van den Maagdenberg, A.M.J. 1 

1 2 Department of Human Genetics, Leiden University Medical Centre (LUMC), Netherlands; Department of Neurology, Corporació 

Sanitària Parc Taulí, Sabadell, Barcelona, Spain; 3Department of Neurology, Leiden University Medical Centre (LUMC), Netherlands 

P20 A meta-analysis of psychological factors in children with migraine and tension-type headache 

Balottin, U. 1 ; Fusar Poli, P. 2 ; Termine, C. 3 ; Molteni, S. 1 ; Spada, G. 1 ; Nappi, G. 4 ; Galli, F. 4 

1Headache Science Center and Department of Child Neurology and Psychiatry. IRCCS ‘‘C. Mondino National Institute of 

Neurology’’, Italy; 2Department of Psychosis Studies, Institute of Psychiatry, King’s College London, United Kingdom; 3Child Neuropsychiatry Unit, Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy; 4Headache Science 

Centre of the IRCCS ‘National Institute of Neurology C. Mondino’ Foundation, Pavia, Italy 

P21 Migraine without aura: genome-wide association analysis identifies several novel susceptibility 

Loci De Vries, B. 1 ; Freilinger, T. 2 ; Anttila, V. 3 ; Malik, R. 2 ; Terwindt, G.M. 4 ; Pozo-Rosich, P. 5 ; Winsvold, 

B. 6 ; Nyholt, D. 7 ; van Oosterhout, W.P.J. 8 ; Artto, V. 9 ; Todt, U. 10 ; Hämäläinen, E. 3 ; Fernandez-Moralez, J. 3 ; 

Louter, M. 8 ; Kaunisto, M.A. 11 ; Schoenen, J. 12 ; Raitakari, O. 13 ; Lehtimäki, T. 14 ; Ville-Pueyo, M. 15 ; Göbel, H. 16 ; 

Wichman, E. 17 ; Sintas, C. 18 ; Uitterlinden, A. 19 ; Hofman, A. 20 ; Rivadeneira, F. 19 ; Heinze, A. 16 ; Tronvik, E. 21 ; 

van Duin, C.M. 20 ; Kaprio, J. 22 ; Cormand, B. 18 ; Wessman, M. 22 ; Frants, R.R. 1 ; Meitinger, T. 23 ; Müller-Myhsok, 

B. 24 ; Zwart, J.A. 25 ; Färkkilä, M. 9 ; Macaya, A. 15 ; Ferrari, M.D. 4 ; Kubisch, C. 10 ; Palotie, A. 3 ; Dichgans, M. 2 ; van 

den Maagdenberg, A.M.J. 1 

1 2 Department of Human Genetics, Leiden University Medical Centre (LUMC), Netherlands; Institute for Stroke and Dementia 

Research, Klinikum der Universität München, Munich, Germany; 3Wellcome Trust Sanger Institute, Wellcome Trust Genome 

Campus, Cambridge, United Kingdom; 4Department of Neurology, Leiden University Medical Centre (LUMC), Netherlands; 

5 6 Department of Neurology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Spain; Department of 

Neurology, Oslo University Hospital and University of Oslo, Norway; 7Neurogenetics Laboratory, Queensland Institute of Medical 

Research, Brisbane, Australia; 8Department of Neurology, Leiden Medical Centre (LUMC), Netherlands; 9Department of Neurology, 

Helsinki University Central Hospital, Helsinki, Finland; 10Institute of Human Genetics, University of Ulm, Germany; 11Institute for Molecular Medicine Finland (FIMM), University of Helsinki, United Kingdom; 12Headache Research Unit, Department of 

Neurology and Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA)-Neurosciences,, Belgium; 13Department of Clinical 

Physiology, University of Turku and Turku University Central Hospital, Turku, Finland; 14Department of Clinical Chemistry, Tampere 

University Hospital and University of Tampere, Tampere, Finland; 15Pediatric Neurology Research Group, Vall d’Hebron Research 

Institute, Barcelona, Spain; 16Kiel Pain and Headache Center, Kiel, Germany; 17Institute of Epidemiology, Helmholtz Center 

Munich, Neuherberg, Germany; 18Department of Genetics, University of Barcelona, Barcelona, Spain; 19Department of Internal 

Medicine, Erasmus Medical Center, Rotterdam, Netherlands; 20Department of Epidemiology, Erasmus University Medical Center, 

Rotterdam, Netherlands; 21Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; 

22 23 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland; Institute of Human Genetics, Helmholtz 

Zentrum München, Neuherberg, Germany; 24Max Planck Institute of Psychiatry, Munich, Germany; 25Oslo University Hospital and 

University of Oslo, Norway 

P22 Influence of Tohoku-Pacific ocean earthquake on headache cases in the affected area 

Matsumori, Y. 1 ; Fujiwara, S. 2 

1 2 Department of Headache Medicine, Kohnan Hospital, Japan; Department of Neurosurgery, Kohnan Hospital, Japan

EHMTIC20I2 


P23 Self-reported efficacy of complementary and alternative medicine in chronic headache subjects in the 

general population 

Kristoffersen, E.S.; Aaseth, K.; Grande, R.B.; Lundqvist, C.; Russell, M.B. 

Head and Neck Research Group, Research Centre, Akershus University Hospital, Lørenskog, Norway 

P24 A loss-of-function CACNA1A mutation causing benign paroxysmal torticollis of infancy 

Vila-Pueyo, M. 1 ; Sintas, C. 2 ; Flotats, M. 3 ; Gené, G. 4 ; Elorza, X. 4 ; Fernández-Fernández, J.M. 4 ; Cormand, B. 2 ; 

Macaya, A. 1 

1 2 Pediatric Neurology Research Group, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Spain; Departament 

of Genetics, Faculty of Biology, University of Barcelona, Spain; 3Pediatric Neurology Service, Vall d’Hebron Hospital, Spain; 

4Laboratory of Molecular Physiology and Channelopathies, Department of Experimental and Health Sciences, Universitat Pompeu 

Fabra, Spain 

P25 Circadian preference in children and adolescents with migraine - a controlled study 

Gelbmann, G.; Wöber-Bingöl, Ç. 

Department of Child and Adolescent Psychiatry, Medical University of Vienna, Austria 

P26 Screening of cacna1a and ATP1A2 genes in hemiplegic migraine: clinical, genetic and functional studies 

Sintas, C. 1 ; Carreño, O. 1 ; Corominas, R. 1 ; Serra, S.A. 2 ; Vila, M. 3 ; Fernández-Castillo, N. 1 ; Toma, C. 1 ; Pons, 

R. 4 ; Llaneza, M. 5 ; Sobrido, M.J. 6 ; Grinberg, D. 1 ; Valverde, M.A. 7 ; Fernández-Fernández, J.M. 7 ; Macaya, A. 8 ; 

Cormand, B. 1 

1 2 Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Spain; Department of Experimental and Health 

Sciences, UPF, Spain; 3Pediatric Neurology Research Group, Vall d’Hebron, Spain; 4First Department of Pediatrics, Agia Sofia 

Hospital, University of Athens, Athens, Greece; 5Sección de Neurología, Complejo Hospitalario Arquitecto Marcide-Novoa Santos, 

Ferrol, Spain; 6Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain; 7Laboratory of Molecular 

Physiology and Channelopathies, Department of Experimental and Health Sciences, UPF, Spain; 8Pediatric Neurology Research 

Group, Vall d’Hebron Research Institute, Spain 

P27 A clinical study on medication overuse headache in childhood and adolescence 

Piazza, F. 1 ; Chiappedi, M. 2 ; Maffioletti, E. 3 ; Galli, F. 4 ; Spada, G. 3 ; Nappi, G. 4 ; Balottin, U. 1 

1 2 Child Neuropsychiatry Unit – IRCCS “C. Mondino” (Pavia) - Italy, Italy; Don Carlo Gnocchi ONLUS Foundation – Milan – Italy, 

Italy; 3Child Neuropsychiatry, University of Pavia, Italy; 4Headache Science Centre of the IRCCS ‘National Institute of Neurology C. 

Mondino’ Foundation, Pavia, Italy, Italy 

P28 The importance of co-morbidity and environmental risk factors for the development of migraine 

Le, H. 1 ; Tfelt-Hansen, P. 1 ; Skytthe, A. 2 ; Kyvik, K.O. 3 ; Olesen, J. 1 

1 2 Glostrup Hospital/Danish Headache Center, Denmark; University of Southern Denmark/The Danish Twin Registry, Denmark; 

3University of Southern Denmark/Institute of Regional Health Services Research, Denmark 

P29 17β-estradiol and methylation of migraine-related genes. 

Labruijere, S.; Verbiest, M.; De Vries, R.; Danser, A.H.J.; Uitterlinden, A.G.; Stolk, L.; 

MaassenVanDenBrink, A. 

Erasmus Medical Center, Netherlands 

P30 Headache disorders in a tertiary care headache outpatient clinic in Austria 

Fischer, M.; Wille, G.; Klien, S.; Broessner, G. 

Innsbruck Medical University, Austria 

P31 Me and my migraine: impact survey for children and young people 

Burn, D. 1 ; Markham, R. 1 ; Lipscombe, S. 2 ; Abu-Arafeh, I. 3 

1 2 3 Migraine Association, United Kingdom; Royal Sussex Hospital, United Kingdom; Forth Valley Royal Hospital, United Kingdom 

P32 Headache and wine. Are all wines the same? 

Diaz-Insa, S. 1 ; Rodrigo, A. 1 ; Pamblanco, Y.M. 2 ; Lacruz, L. 2 ; Soler, A. 2 ; Guillen, C. 2 

1 2 Headache-Neurology Unit, Spain; Neurology Unit, Spain 

41

42 

EHMTIC20I2 



contInued 

P33 Childhood’s chronic headache in children’s national hospital of Albert Royer in Dakar 

Seck, L.B. 1 ; Diagne, N.S. 1 ; Sow, A.D. 1 ; Ndiaye, M. 1 ; Gueye, L. 1 ; Sow, D. 2 ; Diop, A.G. 1 ; Ndaiye, M.M. 1 

1 Fann Teaching Hospital, Senegal; 2 Albert Royer Children National Hospital, Senegal 

P34 Elucidating the molecular genetic basis of cluster headache: delineation of the genetic architecture by 

exome sequencing 

Southgate, L. 1 ; Scollen, S. 2 ; He, W. 3 ; Moss, A. 4 ; Simpson, M.A. 1 ; Zhang, B. 3 ; Xi, L. 3 ; Schlitt, T. 1 ; Weale, 

M.E. 1 ; Hyde, C.L. 3 ; Stephens, J.C. 3 ; Sjöstrand, C. 5 ; Russell, M.B. 6 ; Leone, M. 7 ; John, S.L. 3 ; Trembath, R.C. 1 

1 2 Department of Medical & Molecular Genetics, King’s College London, Guy’s Hospital, London, United Kingdom; Pfizer, Neusentis, 

PTx Precision Medicine, Granta Park, Cambridge, United Kingdom; 3Pfizer, PTx Precision Medicine, Eastern Point Road, Groton CT, 

United States; 4Pain & Sensory Disorders, Pfizer, Neusentis, Granta Park, Cambridge, United Kingdom; 5Department of Neurology, 

Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden; 6Head and Neck Research Group, Research 

Centre, Akershus University Hospital, Oslo, Norway; 7Carlo Besta National Neurological Institute, Milan, Italy 

P35 Naturalistic study of the joint presence of headache and pets 

Moscato, D.; Calabrese, B.; Moscato, F.R. 

IDI Sanità, via Monti di Creta 104 00165 Roma, Italy 

14.30-16.00 

posTEr sEssIon b: 

oTHEr prIMary HEadaCHEs: TEnsIon-TypE HEadaCHE and oTHEr TaCs and oTHEr 

prIMary HEadaCHEs 

14.30-15.10 Poster viewing P36-P64, LB07, LB09, LB12, LB14, LB15 – Exhibition area 

15.10-15.20 Break 



Authors of odd numbers (P37, P39, 415, etc) will attend their poster for the first 20 minutes of the poster viewing 



P36 A translational in vivo model of trigeminal autonomic cephalalgias – therapeutic characterization with 

brainstem stimulation 

Akerman, S.; Holland, P.R.; Summ, O.; Lasalandra, M.P.; Goadsby, P.J. 

University of California, San Francsico, United States 

P37 Long-term efficacy of Boswellia serrata in 4 patients with chronic cluster headache 

Lampl, C. 1 ; Haider, B. 2 ; Schweiger, C. 3 

1 2 3 Hospital of Sisters of Mercy, Linz, Austria; LNK Wagner Jauregg, Linz, Austria; Barmherzige Brüder Linz, Austria 

P38 Common diagnostic/therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: 

a systematic review 

Viana, M.; Tassorelli, C.; Allena, M.; Nappi, G.; Antonaci, F. 

Headache Science Center - C. Mondino National Institute of Neurology Foundation, IRCCS, Italy 

P39 Characteristics of primary exertional headache in Korean marine corps 

Cho, B.H. 1 ; Choi, Y.U.N. 1 ; Nam, T.S. 2 ; Choi, S.M. 2 ; Lee, S.H. 1 ; Park, M.S. 1 ; Kim, M.K. 1 

1 2 Department of Neurology, Chonnam National University Medical School, Gwangju, Korea, Republic of; Department of Neurology, 

Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of

EHMTIC20I2 


P40 The efficacy of neurotropin in treating patients with nummular headaches 

Danno, D.; Tachibana, H. 

Hyogo College of Medicine, Japan 

P41 Diagnostic distribution of 100 strictly unilateral headaches consulting in a specialised clinic 

Ramon, C.; Mauri, G.; Vega, J.; Para, M.; Rico, M.; Moris, G.; Pascual, J. 

University Hospital Central de Asturias, Spain 

P42 The borderline between cluster headache and migraine: does cluster-migraine exist? 

Lisotto, C. 1 ; Mainardi, F. 2 ; Maggioni, F. 1 ; Zanchin, G. 1 

1 Headache Centre, University of Padua, Italy; 2 Headache Centre, Hospital of Venice, Italy 

P43 Clinical profile of probable cluster headache without ipsilateral autonomous symptoms 

Imai, N. 

Japanese Red Cross Shizuoka Hospital, Japan 

P44 Efficacy and reproducibility of response of greater occipital nerve blocks in chronic cluster headache: a 

large-sample prospective analysis 

Abu Bakar N.; Lambru, G.; Stahlhut, L.; Shanahan, P.; Matharu, M.S. 

Headache Group, United Kingdom 

P45 Fast and slow titration of verapamil in cluster headache: comparison of electrocardiographic abnormalities 

Chan, C.K.; Lambru, G.; Matharu, M.S. 


P46 Post-traumatic cluster headache: a clinical phenotype study of 16 patients 

Lambru, G.; Chan, C.K.; Matharu, M.S. 


P47 Effectiveness of antidepressants for treatment of idiopathic orofacial pain 

Ikawa, M. 1 ; Ikawa, M. 2 

1 2 Shimizu Municipal Hospital, Japan; Shimizu Municipal Hospital, Dept. of Oral Surgery, Japan 

P48 Tension type headache is dead; long live chronic migraine! 

Elrington, G.E. 

National Migraine Centre, United Kingdom 

P49 Pain referral patterns of the C1-C3 nerve roots: implications for headache disorders and the development of 

new therapies 

Johnston, M.; Jordan, S.; Charles, A. 

UCLA School of Medicine, United States 

P50 Paroxysmal hemicrania-tic syndrome: a new case report 

Maestrini, I.; Viganò, A.; Di Stefano, G.; Truini, A.; Cruccu, G.; Lenzi, G.L.; Di Piero, V. 

Department of Neurology and Psychiatry, ‘Sapienza’ University of Rome, Rome, Italy 

P51 Trigeminal pain is suppressed by non-invasive vagal nerve stimulation in a rat headache model 

Oshinsky, M.L. 1 ; Murphy, A.L. 2 ; Cooper, M.E. 2 ; Simon, B.J. 3 

1 2 3 Thomas Jefferson University, United States; Thomas Jefferson Unversity, United States; ElectroCore LLC., United States 

P52 Does tension-type headache patients have a reduced shoulder muscle strength compared to healthy controls? 

Madsen, K.B. 1 ; Andersen, L.L. 2 ; Skotte, J. 2 ; Jensen, R. 1 

1 2 Danish Headache center Department of Neurology Glostrup Hospital., Denmark; Danish National Research Centre for the Working 

Environment, Denmark 

43

44 

EHMTIC20I2 



contInued 

P53 Relations between tension-type headache, sleep problems and temporomandibular pain? 

Caspersen, N. 1 ; Hirsvang, J.R. 1 ; Kroell, L. 1 ; Jadidi, F. 2 ; Baad-Hansen, L. 2 ; Svensson, P. 2 ; Jensen, R. 1 

1 Danish Headache Center, Department of Neurology, Glostrup Hospital,University of Copenhagen, Denmark; 2 Section of Clinical 

Oral Physiology, Departement of Dentistry, University of Aarhus, Denmark 

P54 Can cigarette smoking worsen the clinical course of cluster headache? 

Tiraferri, I.; Righi, F.; Zappaterra, M.; Ciccarese, M.; Pini, L.A.; Ferrari, A.; Cainazzo, M.M. 

Headache and Drug Abuse Interdepartmental Research Centre and Anti-smoking Centre University of Modena and Reggio Emilia, Italy 

P55 Accessibility of headache centers for patients suffering for cluster headache in Italy: too far from the 

patients’ needs 

Rossi, P. 1 ; Geraci, C. 2 ; Tassorelli, C. 3 ; Nappi, G. 3 

1 2 3 Headache Centre INI Grottaferrata, Italy; AlCe Cluster Europe, Germany; IRCCS C Mondino Pavia, Italy 

P56 Effect of homeopathy on chronic tension-type headache: A pragmatic, randomised controlled single blind trial 

Sharma, N. 1 ; Ameta, A. 1 ; Sharma, s. 2 

1 2 NMP Medical Research Institute, India; Medical Directorate, Govt. of Rajasthan, India 

P57 Pathway ch-1 study: sphenopalatine ganglion (spg) stimulation for acute treatment of chronic cluster 

headache (CCH) 

Schoenen, J. 1 ; May, A. 2 ; Jensen, R. 3 ; Láinez, M. 4 ; Lantéri-Minet, M. 5 ; Gaul, C. 6 ; Goodman, A. 7 ; Caparso, A. 7 

1 2 3 CHR de la Citadelle, Liège University, Belgium; Universitäts-Krankenhaus Eppendorf, Germany; Glostrup Hospital, University 

of Copenhagen, Denmark; 4Hospital Clinico Universitario, Universidad de Valencia, Spain; 5Hôpital Pasteur, France; 6University Duisburg-Essen, Germany; 7Autonomic Technologies, Inc., United States 

P58 Pericranial muscle tenderness in a population based sample of chronic tension-type headache. The Akershus 

study of chronic headache 

Aaseth, K.; Grande, R.B.; Lundqvist, C.; Russell, M.B. 

Head and Neck Research Group, Research Centre, Akershus University Hospital, Norway 

P59 New recipes for old ingredients: high doses of methylprednisolone and verapamil in cluster headache 

Zanchin, G. 1 ; Disco, C. 2 ; Mainardi, F. 3 ; Mampreso, E. 4 ; Lisotto, C. 5 ; Maggioni, F. 2 

1 2 Headache Centre of Veneto Region, Department of Neurosciences, University of Padua, Italy; Headache Centre of the Veneto 

Region, Department of Neurosciences, University of Padua, Italy; 3Headache Centre of SS Giovanni e Paolo Hospital, Venice, Italy; 

4 5 Headache Centre of Piove di Sacco Hospital (Padua), Italy; Headache Centre of of S. Vito al Tagliamento Hospital, Italy 

P60 Efficacy and safety of occipital nerve blocks in cluster headache: a prospective observational study 

Gaul, C. 1 ; Roguski, J. 2 ; Shanib, H. 2 ; Totzeck, A. 2 ; Görlinger, K. 3 ; Diener, H.C. 3 ; Weber, R. 4 

1 2 3 Migraine- and Headache Clinic Königstein, Germany; Headache Center University Hospital Essen, Germany; University Hospital 

Essen, United Kingdom; 4University Hospital Essen, Germany 

P61 Knowledge, attitudes and clinical practice regarding behavioral treatments and psychological issues in 

migraine: A survey of AHS members 

Buse, D.C. 1 ; Andrasik, F. 2 ; Lipton, R.B. 1 ; Sollars, C.M. 3 ; McMichael, A.D. 4 ; Nicholson, R.A. 4 

1 2 3 Albert Einstein College of Medicine, United States; University of Memphis, United States; Montefiore Headache Center, United 

States; 4Mercy Clinic Headache Center, United States 

P62 Clinical characteristics and pharmacological treatment of new daily persistent headache (NDPH) 

Tachibana, H.; Danno, D. 

Hyogo College of Medicine, Japan 

P63 Methyprednisolone i.v. alters levels of CGRP and melatonin in cluster headache patients 

Neeb, L.; Anders, L.; Euskirchen, P.; Hoffmann, J.; Reuter, U. 

Charite Universitaetsmedizin Berlin, Germany

EHMTIC20I2 


P64 Side locked headaches 

Momoh-Ojewuyi, A.; Ayubi, A.; Abusamra, R.; Al-Ani, S.; Whitehouse, A.; Alkilani, R.; Ahmed, M.A.S. 

Barking Havering & Redbridge NHS Trust, United Kingdom 


09.15-10.45 

posTEr sEssIon C: 

basIC sCIEnCE: MIgraInE-basIC ExpErIMEnTal sCIEnCE and paTHopHysIology 


09.55-10.05 Break 






P65 Greater occipital nerve block in management of chronic migraine; exploring clinical effectiveness and 

patient experience 

Williamson, J.C.; Winston, J.; De Silva, R. 

Essex Centre for Neurosciences, United Kingdom 

P66 Cortical spreading depression impairs hippocampal long-term potentiation by the alteration of glutamate 

receptor responses 

Bongsebandhu-Phubhakdi, S.; Maneepark, M.; Srikiatkhachorn, A. 

Department of Physiology, Faculty of Medicine, Chulalongkorn University, Thailand 

P67 GABAA receptors in the nucleus raphe magnus modulate firing of neurons in the trigeminocervical complex 

Supronsinchai, W.; Storer, R.J.; Hoffmann, J.; Andreou, A.P.; Akerman, S.; Goadsby, P.J. 

Headache Group, Department of Neurology, United States 

P68 Effects of URB937 on an animal model of migraine pain 

Greco, R. 1 ; Mangione, A.S. 1 ; De Icco, R. 1 ; Bandiera, T. 2 ; Sandrini, G. 3 ; Nappi, G. 3 ; Piomelli, D. 4 ; Tassorelli, C. 3 

1 2 Headache Science Centre, IRCCS National Neurological Institute “C. Mondino” Foundation , Pavia, Italy; Medicinal Chemistry 

Drug Discovery and Development, Italian Institute of Technology, Genova,Italy, Italy; 3Headache Science Centre, IRCCS National 

Neurological Institute “C. Mondino” Foundation , UCADH Pavia, Italy, Italy; 4Departments of Pharmacology and Biological 

Chemistry, University of California, Irvine, CA, USA, United States 

P69 KCl-induced repetitive cortical spreading depression inhibits trigeminal neuronal firing mediated by 

5-HT1B/1D and opioid receptor 

Supronsinchai, W.; Hoffmann, J.; Akermann, S.; Goadsby, P.J. 

Headache Group, Department of Neurology, United States 

P70 Role for TRPA1 receptor channels in trigeminal afferent activation and neuropeptide release from rat cranial 

dura mater 

Albrecht, S.; Denner, A.C.; Eberhardt, M.; DeCol, R.; Messlinger, K.B. 

Institute of Physiology & Pathophysiology, University of Erlangen-Nuernberg, Germany 

45

46 

EHMTIC20I2 



contInued 

P71 Magnesium and memantine do not inhibit nociceptive neuronal activity in the trigeminocervical complex 

of the rat 

Hoffmann, J.; Park, J.W.; Storer, R.J.; Goadsby, P.J. 

Headache Group - Department of Neurology, University of California San Francisco, United States 

P72 Role of TRPV-1 in CGRP-mediated trigeminal sensitization 

Chatchaisak, D. 1 ; Chetsawang, B. 2 ; le Grand, S.M. 3 ; Govitrapong, P. 2 ; Srikiatkhachorn, A. 4 

1Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol Universit, Salaya, Nakhonpathom 73170, 

Thailand; 2aResearch Center for Neuroscience, Institute of Molecular Biosciences, Mahidol Universit, Salaya, Nakhonpathom 

73170, Thailand; 3Department of Pathology, Faculty of Medicine, Chulalongkorn University, Thailand; 4Deaprtment of Physiology, 

Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 

P73 Dynamic balance decreased in postdromal migraineurs compared to non migraine controls 

Moore, M.T.; Feuerherd, R. 

Northern Michigan University, United States 

P74 Neurocognitive function declines are reversible following migraine headache in college students 

Moore, M.T. 1 ; Covassin, T. 2 ; Pfeiffer, K.A. 2 ; Norris, R.E. 2 ; Jensen, R.L. 1 ; Branta, C.F. 2 

1 2 Northern Michigan University, United States; Michigan State University, United States 

P75 Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B 

and 5-HT1D receptors 

Kori, S. 1 ; Zhang, J. 1 ; Kellerman, D. 1 ; Armer, T. 1 ; Goadsby, P. 2 

1 2 MAP Pharmaceuticals, United States; Dept of Neurology, UCSF, United States 

P76 Modulation of trigeminovascular activity by leptin: a novel antinociceptive mechanism? 

Martins-Oliveira, M.; Hoffmann, J.; Akerman, S.; Goadsby, P.J. 

Headache Group, Department of Neurology, University of California San Francisco, San Francisco CA, United States 

P77 Investigation of 5-HT2B receptor induced dural plasma protein extravasation in a mouse migraine model 

Hunfeld, A.; Segelcke, D.; Andriske, M.; Paris, F.; Zhu, X.; Lübbert, H. 

Ruhr-Universität Bochum, Germany 

P78 Activation of 5-HT2B-receptors leads to increased vasodilation in mouse dura mater blood vessels 

Segelcke, D.; Schulte, C.; Kremser, M.; Hunfeld, A.; Lübbert, H. 

Ruhr University Bochum, LS Animal Physiology, Germany 

P79 Monitoring cortical neuronal activity and spreading depression in freely behaving familial hemiplegic 

migraine Cacna1a R192q knockin mice 

Houben, T. 1 ; Shyti, R. 2 ; Dees, q. 2 ; van Berloo, S. 3 ; de Groote, L. 1 ; Terwindt, G.M. 1 ; Ferrari, M.D. 1 ; 

Tolner, E.A. 1 ; van den Maagdenberg, A.M. 2 

1 2 Department of Neurology, Leiden University Medical Center, Leiden, Netherlands; Department of Human Genetics, Leiden 

University Medical Center, Leiden, Netherlands; 3Instrument Development Department, Leiden University Medical Center, Leiden, 

Netherlands 

P81 Characterization of a novel model for chronic migraine. 

Pradhan, A.; McGuire, B.; Charles, A. 

University of California, Los Angeles, United States 

P82 The effects of botulinum toxin type A on the trigeminal TRPV1 containing neurons innervating the dura mater 

of rat 

Shimizu, T. 1 ; Shibata, M. 1 ; Toriumi, H. 2 ; Iwashita, T. 2 ; Funakubo, M. 2 ; Sato, H. 2 ; Kuroi, T. 2 ; Ebine, T. 2 ; 

Koizumi, K. 2 ; Suzuki, N. 2 

1 2 Keio University, School of Medicine, Japan; Keio University, School of Medicine,, Japan

EHMTIC20I2 


P83 Differential cellular localization of antioxidant enzymes in the trigeminal ganglion 

Shibata, M. 1 ; Sato, H. 1 ; Shimizu, T. 1 ; Shibata, S. 2 ; Toriumi, H. 1 ; Kuroi, T. 1 ; Ebine, T. 1 ; Iwashita, T. 1 ; 

Funakubo, M. 1 ; Akazawa, C. 3 ; Wajima, K. 4 ; Nakagawa, T. 4 ; Okano, H. 2 ; Suzuki, N. 5 

1 Department of Neurology, School of Medicine, Keio University, Japan; 2 Department of Physiology, School of Medicine, Keio 

University, Japan; 3 Department of Biochemistry and Biophysics, Graduate School of Health and Sciences, Tokyo Medical and 

Dental University, Japan; 4 Department of Dentistry and Oral Surgery, School of Medicine, Keio University, Japan; 5 Department of 

Neurology, School of Medicine, Keio University, United Kingdom 

P84 Influence of ovarian hormones on occurrence of cortical spreading depression and its suppression of by 

L-kynurenine in rat 

Chauvel, V.; Multon, S.; Schoenen, J. 

GIGA Neurosciences, Belgium 

P85 Corticosterone enhances CSD susceptibility via glucocorticoid receptor activation in familial hemiplegic 

migraine 1 Cacna1a knock-in mice 

Shyti, R. 1 ; Eikermann-Haerter, K. 2 ; Meijer, O.C. 3 ; van Heiningen, S.H. 1 ; De Groote, L. 4 ; Ferrari, M.D. 5 ; 

Ayata, C. 2 ; van den Maagdenberg, A.M.J. 6 ; Tolner, E.A. 7 

1 2 Dept of Human Genetics, Leiden Univ. Medical Center, Leiden, Netherlands; Neurovascular Research Laboratory, Dept of 

Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States; 3Dept of Endocrinology, Leiden Univ. 

Medical Center, Leiden, Netherlands; 4Dept of Neurology, Leiden Univ. Medical Center, Leiden, Netherlands; 5Dept of Neurology,, 

Netherlands; 6Dept of Human Genetics, Leiden Univ. Medical Center, Leiden, Netherlands; 7Dept Neurology, Leiden Univ. Medical 

Center, Leiden, Netherlands 

P86 Repeated methylene blue administration produces analgesia in experimental pain 

Dondas, A. 1 ; Luca, A. 1 ; Alexa, T. 1 ; Grigoras, V.A. 2 ; Mungiu, O.C. 1 ; Bohotin, C.R. 1 

1Centre for the Study and Therapy of Pain, University of Medicine and Pharmacy, Grigore. T. Popa, Romania, Romania; 

2Department of Neurology, Rehabilitation Hospital, University of Medicine and Pharmacy, Grigore. T. Popa, Romania, Romania 

P87 Chronic cobalt exposure modifies nociception and orofacial inflammatory pain 

Alexa, T. 1 ; Dondas, A. 1 ; Luca, A. 1 ; Grigoras, V.A. 2 ; Mungiu, O.C. 3 ; Bohotin, C.R. 3 

1 2 Centre for the Study and Therapy of Pain, University of Medicine and Pharmacy “Grigore T Popa” Iasi, Romania; Department of 

Neurology, Rehabilitation Hospital, University of Medicine and Pharmacy “Grigore T Popa” Iasi, Romania; 3Centre for the Study 

and Therapy of Pain, Department of Oncology, University of Medicine and Pharmacy “Grigore T Popa” Iasi, Romania 

P88 Involvement of TRPA1 receptors in meningeal blood flow induced by formation of nitroxyl (NO-/HNO) 

Dux, M. 1 ; Eberhardt, M. 2 ; Filipovic, M.R. 3 ; DeCol, R. 2 ; Messlinger, K. 2 

1 2 Department of Physiology, University of Szeged, Hungary; Institute of Physiology & Pathophysiology, University of Erlangen- 

Nuernberg, Germany; 3Department of Chemistry and Pharmacy, University of Erlangen-Nuernberg, United Kingdom 

P89 Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system 

Eftekhari, S.; Warfvinge, K.; W. Blixt, F.; Edvinsson, L 

Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden., Sweden 

P90 Glyceryl trinitrate has opposite effects on different experimental models of pain 

Grigoraay, V.A. 1 ; Luca, A. 2 ; DondaÅŸ, A. 2 ; Alexa, T. 2 ; Mungiu, O.C. 2 ; Bohotin, C.R. 2 

1 2 Department of Neurology, Recovery Hospital, Grigore T Popa University of Medicine and Pharmacy Iasi, Romania; Centre for the 

Study and Therapy of Pain, University of Medicine and Pharmacy, Grigore T Popa University, Iasi, Romania 

P91 CGRP and CGRP receptors in human and rhesus monkey cerebellum 

Eftekhari, S. 1 ; Salvatore, C.A. 2 ; Connolly, B.M. 3 ; O’Malley, S. 3 ; Miller, P.J. 3 ; Zeng, Z. 3 ; Edvinsson, L. 4 

1 2 Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden; Department of 

Pain and Migraine Research, West Point, PA, United States; 3Department of Imaging, Merck Research Laboratories, West Point, 

PA, United States; 4Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden 

P92 Measurements of 17β-estradiol levels in mice for migraine research 

Chan, K. 1 ; Labruijere, S. 1 ; Garrelds, I. 1 ; Danser, A. 1 ; Villalón, C. 2 ; MaassenVanDenBrink, A. 1 

1 2 Erasmus Medical Center, Netherlands; Cinvestav Coapa, Czda, Mexico 

47

48 

EHMTIC20I2 



contInued 

P93 The effect of the CGRP receptor antagonist (MK-8825) on the response to trigeminal nociception in rodents 

Romero-Reyes, M. 1 ; Akerman, S. 2 

1 NYU College of Dentistry, United States; 2 University of California, San Francsico, United States 

P94 Mechanisms of individual differences in heterotopic noxious analgesia (DNIC), an fMRI study 

Vigàno, A. 1 ; Bogdanov, V.B. 2 ; Noirhomme, q. 3 ; Guy, N. 4 ; Dallel, R. 4 ; Laureys, S. 3 ; Phillips, C. 3 ; Schoenen, J. 3 

1 University of Rome La Sapienza, Italy; 2 University of Utah, United States; 3 University of Liège, Belgium; 

4 Université d’Auvergne, France 

P95 Endothelin-converting-enzyme 1 inhibition and CGRP receptor recycling in human coronary and middle 

meningeal arteries 

Labruijere, S. 1 ; De Vries, R. 1 ; Danser, A.H.J. 1 ; Cottrell, G.S. 2 ; MaassenVanDenBrink, A. 1 

14.15-15.45 

posTEr sEssIon d: 

HuMan ExpErIMEnTal sCIEnCE: MIgraInE- ClInICal ExpErIMEnTal sCIEnCE and 

paTHopHysIology 

14.15-14.55 Poster viewing P97-P128, LB05, LB08, LB16 – Exhibition area 

14.55-15.05 Break 






P97 The HURT (Headache Under-Response to Treatment) questionnaire: utility in a specialist care center 

in Denmark 

Westergaard, M.L. 1 ; Jensen, R.H. 2 ; Steiner, T.J. 3 

1 2 3 Danish Headache Center, Denmark; Imperial College London, United Kingdom; Norwegian University of Science and 

Technology, Norway 

P98 Brain perfusion permutations during migraine attacks without aura 

Koreshkina, I. 1 ; Khalikov, D. 2 ; Nazinkina, V. 3 ; Amelin, V. 4 ; Osipova, V. 5 

1 2 Ltd AVA-PETER, Russian Federation; Saint Petersburg State Medical Academy named after I. I. Mechnikov, Russian Federation; 

3Laboratory of Neurovisualization, Institute of the Human Brain of the Russian Academy of Sciences, Russian Federation; 

4Neurology Department, Saint Petersburg State Medical University named after Academician I. P. Pavlov, Russian Federation; 

5Department of Neurology and Clinical Neurophysiology, First Moscow Medical University named after I. M. Sechenov; General 

Secret, Russian Federation 

P99 Headache symptoms of the PREEMPT population 

Dodick, D.W. 1 ; DeGryse, R.E. 2 ; Turkel, C.C. 2 

1 2 Mayo Clinic Arizona, Dept. of Neurology, Phoenix, AZ, United States; Allergan, Irvine, CA, United States 

P100 Evaluation of vestibular evoked myogenic potentials in migraine and migrainous vertigo patients 

ÇatýkerÜtkür, B.; Güneri, A.; Ýdiman, F. 

Dokuz Eylül University, Turkey 

P101 Retrospective trial of influence of atrial septal defect closure on manifestation and prognosis of migraine 

attacks in pediatric patients 

Lizunou, Y.S. 1 ; Fedulov, A.S. 1 ; Procenko, E.U. 2 ; Goncharik, D.B. 2 ; Chesnov, U.M. 2 

1 2 Belarussian State Medical University, Belarus; Republican Research and Clinical Centre “Cardiology”, Belarus

EHMTIC20I2 


P102 Headache, migraine, brain lesion and MRI study 

Radojkovic Gligic, N.; Amanovic Curuvija, R.; Kacar, K. 

Hospital for cerebrovascular desease St. Sava, Serbia and Montenegro 

P103 Determination of anxiety, mood disorders and disability in cluster and migraine headache 

Gonzalez, C.; Benitez, S.; Gomez, T.; Bernal, M.; Jimenez, M.D. 

Virgen del Rocio Universitary Hospital, Spain 

P104 Increased levels of CGRP in peripheral blood in women with chronic migraine: A reliable biological marker 

Cernuda-Morollon, E. 1 ; Larrosa, D. 2 ; Moris, G. 2 ; Ramon, C. 2 ; Pascual, J. 2 

1 University of Oviedo, Spain; 2 University Hospital Central de Asturias, Spain 

P105 High prevalence of right to left shunt in women with chronic migraine 

Larrosa, D.; Benavente, L.; Calleja, S.; Gonzalez-Delgado, M.; Pascual, J. 


P106 Clinical and imaging approach to headache in patients with multiple sclerosis 

Voiticovschi-Iosob, C.; Moldovanu, I. 

State Medical and Pharmaceutical University “Nicolae Testemitanu”, Moldova, Republic of 

P107 Migraine in neurological department of fann teaching hospital in Dakar 

Seck, L.B. 1 ; Ba, M. 1 ; Toure, K. 1 ; Thiam, A. 1 ; Diop, A.G. 2 ; Ndiaye, M.M. 1 

1 Neurological Department - Fann Teaching Hospital, Senegal; 2 Neurological Department - Fann Teaching Hospital, Senegal 

P109 Associations between cerebral and systemic endothelial function in migrane patients 

Pretnar-Oblak, J.P.O.; Zvan, B.Z.; Zaletel, M.Z. 

University Clinical Center Ljubljana, Slovenia 

P110 Provocation of migraine with aura using natural trigger factors 

Hougaard, A.; Amin, F.M.; Hauge, A.W.; Ashina, M.; Olesen, J. 

Danish Headache Center, Department of Neurology, University of Copenhagen, Faculty of Health Sciences, Denmark 

P111 Overreaction to non noxious vascular stimuli in migraine and effect of NMDA receptor blockade 

Nicolodi, M. 

Foundation Prevention and Therapy Primary Pain, Italy 

P112 Imaging the premonitory phase of migraine - new insights into generation of the migraine attack 

Maniyar, F.H. 1 ; Sprenger, T. 2 ; Schankin, C. 3 ; Goadsby, P.J. 3 

1 Pinderfields General Hospital, NHS Trust, United Kingdom; 2 University Hospital Basel, Switzerland, Switzerland; 3 University 

of California, San Francisco, United States 

P113 Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura 

Antonova, M.; Wienecke, T.; Olesen, J.; Ashina, M. 


P114 Prostaglandins and prostaglandin receptor antagonism in migraine 

Antonova, M. 


P115 Other cortical dysfunctions during visual and sensitive migraine aura 

Zidverc-Trajkovic, J.Z.T. 1 ; Petrusic, I.P. 2 ; Podgorac, A.P. 2 ; Radojicic, A.R. 1 ; Sternic, N.S. 3 

1 Headache Center, Neurology Clinic, Cilinical Center of Serbia, Serbia and Montenegro; 2 School of Medicine, Unversity of Belgrade, 

Serbia, Serbia and Montenegro; 3 Headache Center, Neurology Clinic, Cilinical Center of Serbia, United Kingdom 

49

50 

EHMTIC20I2 



contInued 

P116 Effectiveness of integrated yoga therapy in treatment of chronic migraine: Randomized controlled trial 

Sharma, N. 1 ; Singhal, S. 1 ; Singh, A.P. 1 ; Sharma, C.M. 2 

1 NMP Medical Research Institute, India; 2 Sms medical college and hospital, India 

P117 The frequency of postdromal symptoms in patients suffering from migraine 

Stanic, I.; Sretenovic, L.J. 

Headache and Migraine Centre, Serbia and Montenegro 

P118 Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS- 

927711 in healthy subjects 

Tong, G.; Savant, I.; Jariwala, N.; Burt, D.; Zheng, N.; Buzescu, A.; Bertz, R.; Keswani, S.; Marcus, R. 

Bristol-Myers Squibb, United States 

P119 Postural sway in migraine patients and controls, results from a population based CAMERA-2 study 

Koppen, H. 1 ; Palm-Meinders, I.H. 2 ; Horlings, C.G.C. 3 ; Terwindt, G.M. 2 ; Launer, L.J. 4 ; van Buchem, M.A. 2 ; 

Kruit, M.C. 2 ; Bloem, B.R. 3 ; Ferrari, M.D. 2 

1 2 3 Hagahospital, Netherlands; Leiden University Medical Center, Netherlands; Radboud University Nijmegen Medical Centre, 

Netherlands; 4Laboratory of epidemiology, demography and biometry, United States 

P120 The effect of the cold pressor test on a visually evoked cerebral blood flow velocity response in patients 

with migraine 

Fabjan, A. 1 ; Vidmar, J. 1 ; Musizza, B. 2 ; Bajrović, F.F. 3 ; Zaletel, M. 4 ; Štrucl, M. 1 

1 2 Institute of Physiology, Medical Faculty, University of Ljubljana, Slovenia, Slovenia; Jožef Stefan Institute, Ljubljana, Slovenia, 

Slovenia; 3Institute of Pathophysiology, Medical Faculty, University of Ljubljana, Slovenia, Slovenia; 4Department of Neurology, 

University Medical Centre of Ljubljana, Slovenia, Slovenia 

P121 Altered thalamic microstructure in migraine without aura patients: a diffusion tensor magnetic resonance 

imaging study 

Coppola, G. 1 ; Tinelli, E. 2 ; Lepre, C. 2 ; Iacovelli, E. 2 ; Di Lorenzo, C. 1 ; Di Lorenzo, G. 3 ; Pauri, F. 2 ; Fiermonte, G. 2 ; 

Bianco, F. 2 ; Pierelli, F. 1 

1 2 Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; Sapienza 

University of Rome, Department of medico-surgical sciences and biotechnologies, Neurology section, Rome, Italy; 3Tor Vergata 

University of Rome, 3Psychiatric Clinic, Department of Neuroscience, Rome, Italy 

P122 Multimodal evoked potentials in chronic migraine 

Coppola, G. 1 ; Iacovelli, E. 2 ; Bracaglia, M. 1 ; Di Lorenzo, C. 1 ; Pierelli, F. 1 

1 2 Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; Sapienza 

University of Rome, Department of medico-surgical sciences and biotechnologies, Neurology section, Rome, Italy 

P123 Influence of varying estrogen levels on trigeminal CGRP release in healthy women 

Ibrahimi, K. 1 ; Danser, A.H.J. 1 ; Villalón, C.M. 2 ; Meiracker, van den, A.H. 1 ; MaassenVanDenBrink, A. 1 

1 2 Erasmus MC, Netherlands; Cinvestav Coapa, Mexico 

P124 Capsaicin-induced CGRP-mediated vasodilatation of the human skin: influence of gender, female hormones 

and migraine 

Vermeersch, S.G.G. 1 ; Frederiks, P. 1 ; Maassen VandenBrink, A. 2 ; de Hoon, J. 1 

1 2 Center for Clinical Pharmacology, University Hospitals Leuven, Campus Gasthuisberg, (KU Leuven), Belgium; Division of Vascular 

Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, Netherlands 

P125 The differences in trigeminal system functional state in chronic and frequent migraine patients 

Pavlic, G. 1 ; Odobescu, S. 1 ; Moldovanu, I. 1 ; Lacusta, V. 2 ; Rotaru, L. 1 ; Corcea, G. 1 

1 2 Institute of Neurology and Neurosurgery, Moldova, Republic of; State Medical and Pharmaceutical University, Moldova, Republic of 

P126 Changes in glutamatergic neurotransmission within the migraine cycle 

Cosentino, G.; Paladino, P.; Fierro, B.; Brighina, F. 

University of Palermo, Italy

EHMTIC20I2 


P127 Migraine days and body mass index (BMI) in a series of Japanese migraineurs 

Takeshima, T. 1 ; Kikui, S. 1 ; Yamashita, S. 1 ; Tominaga, Y. 2 ; Tominaga, S. 2 

1 Neurology, Headache Center, Tominaga Hospital, Japan; 2 Neurosurgery, Tominaga Hospital, Japan 

P128 Pressure pain thresholds in chronic migraine associated with hypertension 

Grosu, O.; Odobescu, S.; Rotaru, L.; Moldovanu, I. 

Institute of Neurology and Neurosurgery, Moldova, Republic of 

15.45-17.15 

posTEr sEssIon E: 

HEadaCHE CarE: dIagnosTICs and oTHEr ClInICal aspECTs of HEadaCHE 


16.25-16.35 Break 






P129 An open-label trial of alsuma auto-injector for migraine 

Ramos, E. 1 ; Landy, S.H. 2 ; Tepper, S.J. 3 ; Wein, T. 4 ; Schweizer, E. 5 

1 2 3 4 Pfizer Inc, United States; Wesley Neurology and Headache Clinic, United States; Cleveland Clinic, United States; McGill 

University, Canada; 5Paladin Consulting Group, United States 

P130 Migraine headache is present in the aura phase – a prospective study 

Hansen, J.M. 1 ; Lipton, R.B. 2 ; Dodick, D.W. 3 ; Silberstein, S.D. 4 ; Saper, J.R. 5 ; Aurora, S.K. 6 ; Goadsby, P.J. 7 ; 

Charles, A. 8 

1Headache Research and Treatment Program, Department of Neurology, University of California Los Angeles, United States; 

22Departments of Neurology, Epidemiology, and Population Health, and the Montefiore Headache Center, United States; 

3 4 Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, United States; Department of Neurology and the Jefferson Headache 

Center, United States; 5Michigan Head Pain and Neurological Institute, Ann Arbor, MI, United States; 6Swedish Pain Center, 

Seattle, WA, United States; 7Headache Group, Department of Neurology, University of California, San Francisco, CA, United States; 

8Headache Research and Treatment Program, Department of Neurology, United States 

P131 Eletriptan provides consistent migraine relief: results of a within-patient multiple-dose study 

Almas, M. 1 ; Tepper, S. 2 ; Landy, S. 3 ; Ramos, E. 1 

1 2 3 Pfizer Inc, United States; Cleveland Clinic, United States; Wesley Neurology and Headache Clinic, United States 

P132 Clinical characterization of “visual snow” (Positive Persistent Visual Disturbance) 

Schankin, C.J.; Maniyar, F.; Hoffmann, J.; Chou, D.; Goadsby, P.J. 

UCSF Headache Center, United States 

P133 Primary sudden onset severe headache: Prognosis and factors influencing it 

KIM, B.K. 

Eulji Hospital, Korea, Republic of 

P134 EEG and transcranial dopplerography of middle cerebral artery in patiens with primary headaches 

Askhonov, U.G.; Askhanov, G.H. 

Neurological clinic “Nevromed-Servis”, Uzbekistan 

51

52 

EHMTIC20I2 



contInued 

P135 Low use of placebo in comparative drug rcts in migraine. Are clinical investigators unaware of basic 

methodological issues? 

Tfelt-Hansen, P.C.; Hougaard, A. 

Danish Headache Centre, Denmark 

P136 Relationship between migraine and malocclusion 

Takeuchi, M. 1 ; Kato, M. 1 ; Saruta, J. 2 ; Tsukinoki, K. 2 ; Igarashi, H. 3 

1 2 Department of Craniofacial Growth and Development Dentistry, Kanagawa Dental College., Japan; Department of Oral Pathology, 

Division of Salivary Gland Health Medicine, Kanagawa Dental College, Japan; 3Department of Internal Medicine, Yokohama Medical 

and Dental clinic, Kanagawa Dental College, Japan 

P137 Chronic migraine is not associated with cerebellar infarct-like lesions 

Meilan, A.; Santamarta, E.; Saiz, A.; Larrosa, D.; Cernuda, E.; Pascual, J. 


P138 The comorbidity between migraine and hypothyroidism 

Lisotto, C. 1 ; Mainardi, F. 2 ; Maggioni, F. 1 ; Zanchin, G. 1 

1 2 Headache Centre, University of Padua, Italy; Headache Centre, Hospital of Venice, Italy 

P139 Cardiovascular activity in migraine patients: Influence of age and headache chronification 

Grosu, O.; Odobescu, S.; Moldovanu, I.; Rotaru, L. 

Institute of Neurology and Neurosurgery, Moldova, Republic of 

P140 Altered affective response to exercise is changed after moderate aerobic exercise training in migraine 

Belitardo de Oliveira, A. 1 ; Teixeira Ribeiro, R. 1 ; Souza Carvalho, D. 1 ; Mello, M.T. 1 ; Tufik, S. 1 ; Prieto Peres, M.F. 2 

1 2 Universidade Federal de São Paulo - Brazil, Brazil; Universidade Federal de São Paulo, Brazil 

P141 Can induced headache be used in the differential diagnosis of primary headaches as a diagnostic tool? 

Fethi Ýdiman, Gökhan Gürel, Ýdiman, F.E.T.; Gürel, G.o.k. 

Dokuz Eylül University, Turkey 

P142 Usefulness and applicability of web-based headache diagnostic software 

Radojicic, A. 1 ; Nikolic, M. 2 ; Zidverc-Trajkovic, J. 1 ; Podgorac, A. 1 ; Sternic, N. 1 

1 2 Headache Center, Neurology Clinic, Clinical Center of Serbia, Serbia and Montenegro; Faculty of Mathematics, University 

of Belgrade, Serbia, Serbia and Montenegro 

P143 Analysis of subjects with menstrually related migraine vs. Non-menstrually related migraine treated with 

MAP0004 

Aurora, S. 1 ; Lu, B. 2 ; Connors, E. 2 ; Li, X. 2 ; Kellerman, D. 2 ; Kori, S. 2 

1 2 Swedish Neuroscience Institute, Swedish Headache Center, Seattle, WA, United States; MAP Pharmaceuticals, United States 

P144 Is ischemic stroke more severe in patients with migraine vs. other headache types? 

Maticiuc, V.; Moldovanu, I.; Odobescu, S.; Grosu, O. 

National Institute of Neurology and Neurosurgery, Moldova, Republic of 

P145 Darling, the doctor says I slept well but I still have headache in the morning: An actigraphic study in couples 

Seidel, S. 1 ; Frantal, S. 2 ; Oberhofer, P. 1 ; Bauer, T. 1 ; Scheibel, N. 1 ; Albert, F. 1 ; Casjens, T. 1 ; Klösch, G. 1 ; 

Zeitlhofer, J. 1 ; Wöber, C. 1 

1 2 Department of Neurology, Medical University of Vienna, Austria; Department of Medical Statistics, Medical University of Vienna, 

Austria 

P146 Can DoloTest predict the efficacy of Psychological treatment in patients suffering from severe headache? 

Zimmer, T.; Kjeldgaard, D. 

Danish Headache Center, Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark, Denmark

EHMTIC20I2 


P147 Catastrophizing and pain impact in migraineurs 

Pires, C.; Solé, E.; Miró, J. 

Universitat Rovira i Virgili, Spain 


09.00-10.30 

posTEr sEssIon f: 

sECondary HEadaCHEs 


09.40-09.50 Break 






P148 No increase in headache after previous intracranial infections: a historical cohort study (The Nord-Trøndelag 

Health Survey) 

Linde, M. 1 ; Langnes, H.A. 1 ; Hagen, K. 1 ; Bergh, K. 2 ; Stovner, L.J. 1 

1 2 Department of Neuroscience, Norwegian University of Science and Technology, Norway; Department of Microbiology, St. Olavs 

University Hospital, Trondheim, Norway 

P149 Pain perception is altered in patients with medication-overuse headache but can improve after detoxification 

Munksgaard, S.B.; Bendtsen, L.; Jensen, R.H. 

Danish Headache Center, Dept. of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark 

P150 Detoxification in a structured programme is effective for so-called refractory medication-overuse headache 

Munksgaard, S.B.; Bendtsen, L.; Jensen, R.H. 

Danish Headache Center, Dept. of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Denmark 

P151 Occipital neuralgia secondary to CerebroSpinal fluid leak 

Ansari, H. 

Mayo Clinic, United States 

P152 Migraine in the elderly: Clinical characteristics in a series of 71 cases 

Herrero, S. 1 ; Guerrero, A.L. 2 ; Ruiz, M. 2 ; Pedraza, M.I. 2 ; Mulero, P. 2 ; Barón, J. 2 ; Irene, I. 2 ; De la Cruz, C. 2 ; 

Peñas, M.L. 2 

1 2 Hospital Clinico Universitario, Spain; Neurology Department, Spain 

P153 Clinical analysis of orthostatic headache in Korean patients 

Choi, Y.J. 1 ; Cho, B.H. 1 ; Park, M.H. 1 ; Nam, T.S. 2 ; Kim, J.T. 1 ; Lee, S.H. 1 ; Kim, B.C. 1 ; Kim, M.K. 1 ; Cho, K.H. 1 

1 2 Chonnam National University Hospital, Korea, Republic of; Chonnam National University Hwasun Hospital, Korea, Republic of 

P154 Trigeminal sensitisation by subdural bleeding may mediate brain swelling in acute traumatic brain injury 

Mack, J. 1 ; Squier, W. 2 

1 2 Penn State Hershey Medical Center, United States; John Radcliffe Hospital , Oxford, United Kingdom 

53

54 

EHMTIC20I2 



contInued 

P155 Cognitive, emotional and somatic symptoms among patients with chronic posttraumatic headache. 

A controlled study. 

Kjeldgaard, D. 1 ; Forchhammer, H. 2 ; Jensen, R. 1 

1 2 Danish Headache Centre, Denmark; Glostrup University Hospital, Denmark 

P156 Clinical, EEG and neuroimaging features of ictal epileptic headache 

Radojkovic Gligic, N.Z.R.; Kacar, K.K.K.; Atic, S.M.A.; Vekic, B.V.V. 

Hospital for cerebrovascular desease St. Sava, Serbia and Montenegro 

P157 Tolosa-Hunt syndrome: focus on MRI findings and diagnostic criteria 

Özbenli, T. 1 ; Akpýnar, K. 2 ; Doðru, H. 2 ; Ýncesu, L. 1 

1 2 Ondokuz Mayýs University, Turkey; Ondokuz Mayýs University, United Kingdom 

P158 Carotid-cavernous fistula initially presented with persistent daily headache with promptly neurological 

progression. Case report. 

Ljubisavljevic, S. 1 ; Spasic, M. 1 ; Stojanov, D. 2 

1 2 Clinic for Neurology, Clinical centre of Nis, Serbia and Montenegro; Center for Radiology, Clinical centre of Nis, Serbia 

and Montenegro 

P159 quantitative sensory testing in atypical odontalgia patients after local anesthesia 

Porporatti, A.L.; Conti, P.C.R. 

Bauru School of Dentistry, Brazil 

P160 Impact of hypertension on somatic pain sensitivity in chronic headache 

Tafuri, E.T. 1 ; Di Fabio, S. 2 ; Cozza, E. 3 ; Affaitati, G.P. 1 ; Fabrizio, A. 4 ; Tana, C. 3 ; Felicioni, L. 5 ; Bucci, M. 6 ; 

Mezzetti, A. 6 ; Giamberardino, M.A. 7 

1 2 Headache Center and Center for the Study of Hypertension, G. D’Annunzio University of Chieti,Italy; Headache Center, G. 

D’Annunzio University of Chieti, Italy; 3Headache Center , G. D’Annunzio University of Chieti, Italy; 4Headache Center G. 

D’Annunzio University of Chieti, Italy; 5Headache Center, G. D’Annunzio” University of Chieti, Italy; 6Center for the Study of 

Hypertension, G. D’Annunzio University of Chieti, Italy; 7Headache Center, G. D’Annunzio University of Chieti, Italy 

P161 Great auricular neuralgia: Case series 

Robertson, C.E.; Garza, I. 

Mayo Clinic, Rochester, MN, United States 

P162 Medication overuse headache is a manifestation of opioid induced hyperalgesia: A neuroimmune hypothesis 

and novel approach to treatment 

Rolan, P.; Johnson, J.L. 

University of Adelaide, Australia 

P163 Syndrome of headache with neurologic deficits and CSF lymphocytosis (HaNDL) 

Skorobogatykh, K.; Azimova, Y.; Tabeeva, G. 

1st Moscow State Medical University, Russian Federation 

P164 Use of acute anti-migraine medication and risk of development of chronic headache: a prospective 

population based study 

Schramm, S. 1 ; Yoon, M.S. 2 ; Katsarova, A. 1 ; Obermann, M. 3 ; Fritsche, G. 3 ; Moebus, S. 1 ; Katsarava, Z. 4 

1 2 Institute of Medical Informatics, Biometry and Epidemiology, University Duisburg-Essen, Germany; Department of Neurology, 

Ruhr-University Bochum, Germany; 3Department of Neurology and Headache Center, University Duisburg-Essen, Germany; 

4Department of Neurology, Evangelisches Krankenhaus Unna, Germany 

P165 A giant cause of a low pressure headache 

Miller, S. 1 ; Overell, J. 2 ; Jampana, R. 3 ; Gorrie, G. 1 ; Tyagi, A. 1 ; Gilles, C. 1 ; McKenzie, M. 1 

1 2 Glasgow Headache Group, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom; Department 

of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom; 3Department of 

Neuroradiology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom

EHMTIC20I2 


P166 Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial 

hypertension 

Skau, M. 1 ; Yri, H. 1 ; Gerds, T. 2 ; Jensen, R. 1 

1 2 Danish Headache Centre, Department of Neurology, Denmark; Department of Biostatistics Copenhagen, University of 

Copenhagen, Denmark 

P167 Idiopathic intracranial hypertension is not benign; a prospective long-term follow-up study 

Yri, H. 1 ; Wegener, M. 2 ; Sander, B. 2 ; Jensen, R. 1 

1 2 Danish Headache Centre, Department of Neurology, Denmark; Department of Ophthalmology, Glostrup Hospital, University of 

Copenhagen, Denmark 

P168 Transcranial magnetic stimulation as a new approach in medication overuse headache: A pilot study 

Granato, A. 1 ; Musho Ilbeh, S. 1 ; Trovò, F. 1 ; Borelli, M. 2 ; Granello, G. 1 ; Semenic, M. 1 ; Monti, F. 1 ; Pizzolato, G. 1 

1 2 Department of Medical, Surgical and Health Sciences, Headache Centre, University of Trieste, Trieste, Italy; Department of 

Mathematics and Geosciences, University of Trieste, Trieste, Italy 

P169 Coexistence of “headache attributed to airplane travel” and “mountain descending headache” 

Mainardi, F. 1 ; Maggioni, F. 2 ; Lisotto, C. 3 ; Zanchin, G. 2 

1 2 Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy; Headache Centre, Department of 

Neurosciences, Padua University, Padua, Italy; 3Headache Centre, San Vito al Tagliamento Hospital, San Vito al Tagliamento, Italy 

P170 Synovial cyst of temporomandibular joint, a potential etiology for auriculotemporal neuralgia? 

Ansari, H.; Robertson, C.B.E.; Garza, I. 

Mayo Clinic, United States 

P171 Headache as a symptom of Multiple Sclerosis 

Kalamatas, T.; Protopapas, N.; Vasiliadis, E.; Karanasiou, P.; Karageorgiou, K. 

GNA G.Gennimatas, Greece 

P172 Neuroimaging, neuropsychological and psychopathological findings in Medication Overuse Headache (MOH) 

before and after detoxification 

Pozo-Rosich, P. 1 ; Cuberas-Borros, G. 2 ; Gomez-Baeza, S. 3 ; Lorenzo-Bosquet, C. 4 ; Jacas, C. 5 ; Alvarez-Sabin, 

J. 5 ; Roncero, C. 6 ; Roncero, C. 3 ; Castell-Conesa, J. 7 

1Headache and Neurological Pain Research Group, Neurology Department, University Hospital Vall d’Hebron, Barcelona, 

Spain; 2Nuclear Medicine Department, University Hospital Vall d’Hebron, Barcelona, Spain; 3Outpatient drug clinic, Psychiatry 

Department, University Hospital Vall d’Hebron, Barcelona, Spain; 4Nuclear Medicine Department, University Hospital Vall 

d’Hebron, Barcelona, United Kingdom; 5Department of Psychiatry and Legal Medicine, Universidad Autonoma de Barcelona, 

United Kingdom; 6Department of Psychiatry and Legal Medicine, Universidad Autonoma de Barcelona., Spain; 7Nuclear Medicine 

Department, University Hospital Vall d’Hebron, Spain 

P173 Predictive factors for the relapse medication overuse headache. A prospective study 

Sergeev, A.; Mesherina, M.; Tabeeva, G. 

Sechenov First Moscow State Medical University, Russian Federation 

P174 The “care” protocol: the role of personality in a three-year follow-up study of medication overuse headache 

Galli, F. 1 ; Sances, G. 1 ; Ghiotto, N. 1 ; Frustaci, A. 2 ; Guaschino, E. 1 ; Nappi, G. 1 ; Tassorelli, C. 1 

1 2 Headache Science Centre of the IRCCS ‘National Institute of Neurology C. Mondino’ Foundation, Pavia, Italy, Italy; Clinical 

and Molecular Epidemiology, IRCCS San Raffaele Pisana, Rome, Italy, Italy 

P175 The “care” protocol: outcome of medication overuse headache in a three year follow-up study 

Sances, G. 1 ; Ghiotto, N. 1 ; Galli, F. 1 ; Allena, M. 1 ; Frustaci, A. 2 ; Guaschino, E. 1 ; Tassorelli, C. 1 ; Nappi, G. 1 

1 2 Headache Science Centre of the IRCCS ‘National Institute of Neurology C. Mondino’ Foundation, Pavia, Italy; Clinical and 

Molecular Epidemiology, IRCCS San Raffaele Pisana, Rome, Italy 

55

56 

EHMTIC20I2 



contInued 

P176 Survey of the differences between Migraine and MOH pre-existing migraine 

Igarashi, H. 

Department of Internal Medicine Yokohama Dental and Medical Clinic Kanagawa Dental College, Japan 

P177 Grey matter changes in medication-overuse headache before and after medication withdrawal 

Riederer, F. 1 ; Gantenbein, A.R. 1 ; Marti, M. 1 ; Luechinger, R. 2 ; Kollias, S. 3 ; Sándor, P.S. 4 

1 University Hospital Zurich, Department of Neurology, Switzerland; 2 Institute for Biomedical Engineering, Swiss Federal Institute 

of Technology and the University of Zurich, Switzerland; 3 Institute of Neuroradiology, University Hospital Zurich, Switzerland; 

4 RehaClinic Bad Zurzach/Baden, Switzerland 

P178 Temperament and character profiles of patients with chronic migraine and medication-overuse headache 

Watanabe, Y.; Tateno, H.; Hirata, K. 

Dokkyo Medical University, Japan 

P179 DNIC in whiplash and ankle-injured controls. 1-year prospective findings 

Kasch, H.; Jensen, T.S. 

Danish Pain Research Center, Denmark 

P180 Treatment and outcome in medication overuse headache patients 

Mitsikostas, D.; Deligianni, I. 

Athens Naval Hospital, Greece 

P181 Occipital locked headache 

Whitehouse, A.; Momoh-Ojewuyi, A.; Abusamara, R.; Al-Ani, S.; Alkilani, R.; Ahmed, M.A.S. 

Barking Havering & Redbridge NHS Trust, United Kingdom 

10.30-12.00 

posTEr sEssIon g: 

MIgraInE THErapy: pHarMaCologICal aCuTE and prEvEnTaTIvE MIgraInE THErapy 


11.10-11.20 Break 






P183 In vitro characterization of AA71, a potent and selective human monoclonal antibody against CGRP receptor 

Shi, L.; Rao, S.; Sun, H.; Wild, K.; Xu, C. 

Department of Neuroscience, Amgen, Inc. Thousand Oaks, California, United States 

P184 Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device 

(PREMICE): a multi-centre, randomized, sham-controlled trial 

Schoenen, J. 1 ; Vandersmissen, B. 2 ; Jeangette, S. 2 ; Herroelen, L. 2 ; Vandenheede, M. 2 ; Gerard, P. 1 ; Magis, D. 1 

1 2 Headache Research Unit, Belgium; Department of Neurology, Belgium 

P186 Review of 500 migraine cases treated with combination of antidepressant & CBT & specific group of dietary 

supplement with 6 month follow up 

Goyal, V.K. 

Parth Hospital, India

EHMTIC20I2 


P187 Hull prospective analysis of Botulinum Toxin type A (Botox) use in the treatment of chronic migraine 

Ahmed, F.; Khalil, M.; quarshie, V. 

Hull and East Yorkshire Hospitals NHS Trust, United Kingdom 

P188 OnabotulinumtoxinA injections for the pain relief and long-term symptom control in a patient with hemiplegic 

migraine: Case study 

Dhawan, P.; Dhawan, P. 

Dhawan Medical Corporation, Canada 

P189 Ornithine in chronic migraine therapy and allodynia pattern: comparison with dopaminergic activation 

Nicolodi, M.; Nicolodi, M. 

Foundation Prevention and Therapy Primary Pain, Italy 

P190 MAP0004 provided consistent migraine pain relief even after repeated administration 

Kori, S.; Lu, B.; Connors, E.; Li, X.; Kellerman, D. 

MAP Pharmaceuticals, United States 

P191 Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, 

randomized, cross-over studies 

Allais, G. 1 ; Tullo, V. 2 ; Omboni, S. 3 ; Benedetto, C. 1 ; Sances, G. 4 ; Zava, D. 5 ; Ferrari, M.D. 6 ; Bussone, G. 2 

1 2 Department of Gynecology and Obstetrics, Women’s Headache Center, University of Torino, Torino, Italy; Department of Clinical 

Neurosciences, Carlo Besta National Neurological Institute, Milano, Italy; 3Italian Institute of Telemedicine, Varese, Italy; 

4 5 Headache Centre, IRCCS C. Mondino Foundation, Institute of Neurology, Pavia, Italy; Istituto Lusofarmaco d’Italia, Milano, Italy; 

6Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Netherlands 

P192 Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, 

multicenter Italian study 

Bartolini, M. 1 ; Giamberardino, M.A. 2 ; Lisotto, C. 3 ; Martelletti, P. 4 ; Moscato, D. 4 ; Panascia, B. 5 ; Savi, L. 6 ; Pini, 

L.A. 7 ; Sances, G. 8 ; Santoro, P. 9 ; Zanchin, G. 10 ; Omboni, S. 11 ; Ferrari, M.D. 12 ; Fierro, B. 13 ; Brighina, F. 13 

1 2 Clinica Neurologica, Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy; Dipartimento di Medicina e Scienze 

dell’Invecchiamento, Università “G. D’Annunzio”, Chieti, Italy; 3Ospedale Civile San Vito al Tagliamento, Pordenone, Italy; 4UOS Cefalea, Ospedale S. Andrea, Università La Sapienza, Roma, Italy; 5Centro Cefalee, A.O. Universitaria Vittorio Emanuele, Catania, 

Italy; 6Department of Neurology, University of Torino, Italy; 7Centro Cefalee, Università degli Studi di Modena e Reggio Emilia, 

Reggio Emilia, Italy; 8Centro Cefalee, IRCCS Neurologico C. Mondino, Pavia, Italy; 9Clinica Neurologica, Ospedale S. Gerardo, 

Monza, Italy; 10Department of Neurology, University of Padova, Italy; 11Italian Institute of Telemedicine, Varese, Italy; 12Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Netherlands; 13Department of 

Neurology and Psichiatry, University of Palermo, Palermo, Italy 

P193 Occipital Nerve Stimulation (ONS) for the treatment of chronic headache syndromes 

Vesper, J. 1 ; Bara, G. 2 ; Kinfe, T.M. 2 ; Schu, S. 2 

1 2 Centre of Neuromodulation, Germany; Functional Neurosurgery, Germany 

P194 Anodal transcranial direct current stimulation of the visual cortex for migraine prevention: 

a proof-of-concept study 

Viganò, A. 1 ; Magis, D. 2 ; Sava, S.L. 2 ; De Pasqua, V. 2 ; Auvé, M. 2 ; Giuliani, A. 3 ; Colosimo, A. 1 ; Di Piero, V. 1 ; 

Schoenen, J. 2 

1 2 3 Sapienza - University of Rome, Italy; ULg - University of Liège, Belgium; Istituto Superiore di Sanità, Italy 

P195 Prophylaxis of migraine with aura: a place for acetylsalicylic acid 

Savi, L.T. 1 ; Condello, C. 1 ; Bert, F. 2 ; Pinessi, L. 3 

1 2 3 Headache Centre, Italy; Department of Public Health, Italy; University of Turin, Italy 

P196 Migraine attacks during menses: efficacy of eletriptan and relationship to recurrence after response 

Bhambri, Almas, Abdulsattar, Chatterjee, 

Pfizer Inc., United States 

57

58 

EHMTIC20I2 



contInued 

P197 OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, 

placebo-controlled phase of PREEMPT 

Dodick, D. 1 ; Diener, H.C. 2 ; Turkel, C. 3 ; DeGryse, R. 3 ; Brin, M. 3 

1 2 3 Mayo Clinic Arizona, United States; University of Essen, United Kingdom; Allergan, United States 

P198 Transcutaneous Vagus Nerve Stimulation (tVNS) for headache prophylaxis: initial experience 

Magis, D.; Gérard, P.; Schoenen, J. 

University Department of Neurology, Belgium 

P199 OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received 

all 5 treatment cycles in PREEMPT 

Aurora, S.K. 1 ; Dodick, D.W. 2 ; DeGryse, R.E. 3 ; Turkel, C.C. 4 

1 2 Swedish Neuroscience Institute, Seattle, WA, United States; Mayo Clinic Arizona, Dept. of Neurology, Phoenix, AZ, United States; 

3 4 Allergan, Irvine, CA, United States; Allergan, Irvine, CA, United States 

P200 The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment 

cycle in the PREEMPT clinical program 

Silberstein, S. 1 ; Dodick, D.W. 2 ; DeGryse, R.E. 3 ; Lipton, R. 4 ; Turkel, C.C. 3 

1 2 3 Thomas Jefferson University, Philadelphia, PA, United States; Mayo Clinic Arizona, Phoenix, AZ, United States; Allergan, Irvine, 

CA, United States; 4Albert Einstein College of Medicine, Bronx, NY, United States 

P201 Acute Treatment Optimization for Migraine: Results of the American migraine Prevalence and Prevention 

(AMPP) study 

Lipton, R.B. 1 ; Manack, A.N. 2 ; Serrano, D. 3 ; Buse, D.C. 4 

1 2 Department of Neurology, Montefiore Medical Center, Bronx, New York, United States; Allergan, Inc., Irvine, California, United 

States; 3Vedanta Research, Chapel Hill, North Carolina, United States; 4Department of Neurology, Montefiore Medical Center, 

Bronx, New York, United States 

P202 Flunarizine is more effective than topiramate in patients with chronic migraine and medication 

overuse headache 

Gracia-Naya, M. 1 ; Hernando-quintana, N. 1 ; García-Gomara, M.J. 2 ; Sánchez-Valiente, S. 2 ; Ríos, C. 3 ; 

Santos- Lasaosa, S. 4 ; Mauri, J.A. 4 ; Artal-Roy, J. 1 ; Latorre-Jimenez, A.M. 5 

1 2 3 4 Hospital Miguel Servet, Spain; Hospital Royo Villanova, Spain; Hospital C. Barbastro, Spain; Hospital Clínico Zaragoza, Spain; 

5Hospital San Jorge. Huesca, Spain 

P203 The ideas of people referred to neurologists about managing their headaches: A qualitative study 

Nadeem, F.; Noble, A.; Ridsdale, L.; Morgan, M. 

Kings College London, United Kingdom 

P204 OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of 

patients without medication overuse 

Diener, H.C. 1 ; Dodick, D.W. 2 ; DeGryse, R.E. 3 ; Turkel, C.C. 4 

1 2 University of Essen, Dept. of Neurology, Essen, Germany; Mayo Clinic Arizona, Dept. of Neurology, Phoenix, AZ, United States; 

3 4 Allergan, Irvine, CA, United States; Allergan, Irvine, CA, United States 

P206 Sumatriptan and dihydroergotamine in proximal and distal human isolated coronary arteries 

Labruijere, S.; Ramirez Rosas, M.B.; De Vries, R.; Danser, A.H.J.; MaassenVanDenBrink, A. 

Erasmus Medical Center, Netherlands 

P207 Application and efficacy of levetiracetam in prophylactic treatment of migraine without aura 

Maykova, T.N. 

Hedache Center Kyiv, Ukraine

EHMTIC20I2 


P208 Efficacy of MAP0004 in treating severe migraine 

Kori, S.; Connors, E.; Zhou, J.; Lu, B.; Borland, S. 

MAP Pharmaceuticals, United States 

P209 EUROLIGHT project: impact of primary headache disorders from a population-based study conducted in Pavia 

Allena, M. 1 ; Tassorelli, C. 1 ; Carugno, B. 2 ; De Icco, R. 1 ; Andree, C. 3 ; Nappi, G. 1 

1 HSC, Headache Science Centre, IRCCS “National Neurological Institute C. Mondino” Foundation and University of Pavia 

and UCADH, Italy; 2 ASL, Azienda Sanitaria Locale of Pavia area, Pavia, Italy; 3 CRP, Centre Recherche Publique, Luxembourg, 

Luxembourg 

P210 The effect of sumatriptan on cephalic arteries - 3T MR-angiography study in healthy volunteers 

Amin, F.M. 1 ; Asghar, M.S. 1 ; Ravneberg, J.W. 1 ; de Koning, P.J.H. 2 ; Larsson, H.B.W. 3 ; Olesen, J. 1 ; Ashina, M. 1 

1 Danish Headache Center & Dept. of Neurology, Denmark; 2 Division of Image Processing, Netherlands; 3 Functional Imaging Unit, 

Department of Diagnostic, Glostrup Hospital, Denmark 

P211 Bilateral jaw dislocation following botulinim toxin type A treatment for chronic migraine 

Forbes, R.B.; Devenney, E. 

Craigavon Area Hospital, United Kingdom 

P212 Consistency vs. switching triptan treatment and headache-related disability: Results of the American 

migraine prevalence & prevention study 

Buse, D.C. 1 ; Serrano, D. 2 ; Kori, S. 3 ; Cunanan, C. 4 ; Manack, A.N. 4 ; Reed, M.L. 2 ; Lipton, R.B. 1 

1 2 3 Albert Einstein College of Medicine, United States; Vedanta Research, United States; MAP Pharmaceuticals, United States; 

4Allergan Inc., United States 

P213 Prophylactic treatments of migraine and GPs in the north of France: Evaluation of practices 

Christian, C.L. 

Service de Neurologie et Pathologie Neurovasculaire, France 

P214 Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention 

(AMPP) study 

Lipton, R.B. 1 ; Serrano, D. 2 ; Kori, S. 3 ; Cunanan, C. 4 ; Manack, A.N. 4 ; Reed, M.L. 2 ; Buse, D.C. 1 

1 2 3 Albert Einstein College of Medicine, United States; Vedanta Research, United States; MAP Pharmaceuticals, United States; 

4Allergan Inc., United States 

P215 Zonisamide is effective in the preventive therapy of chronic migraine 

Belvis, R.; Aceituno, A.; Martinez-Corral, M. 

Dexeus University Insitute, Spain; 

P216 Real-world economic impact of onabotulinumtoxina in patients with chronic migraine 

Rothrock, J.F. 1 ; Bloudek, L.M. 2 ; Houle, T.T. 3 ; Andress-Rothrock, D. 4 ; Hanlon, C. 1 ; Varon, S.F. 5 

1 2 3 The University of Alabama School of Medicine, Birmingham, AL, United States; Allergan, Inc., Irvine, CA, United States; Wake 

Forest University School of Medicine, Winston-Salem, NC, United States; 4University of Alabama Headache, Treatment and 

Research Program, Birmingham, AL, United States; 5Allergan, Inc., Irvine, CA, United States 

59

60 

EHMTIC20I2 


• TEACHING COURSES • SCIENTIFIC SESSIONS • DEBATES • SATELLITE SYMPOSIA • POSTER PRESENTATIONS • EXHIBITS 

www.ihc2013.com 

IHC 2013 IHC 2013 

June 27-30 

John B. Hynes Veterans Memorial Convention Center 

Hosted by the International Headache Society and the American Headache Society ® 

IHC 2013 Scientific Committee 

Michel D. Ferrari, MD, PhD, Leiden, The Netherlands, Co-Chair 

R. Allan Purdy, MD, FAHS, Halifax, Nova Scotia, Co-Chair 

Rami Burstein, PhD, Boston, MA 

Andrew Charles, MD, Los Angeles, CA 

David W. Dodick, MD, FAHS, Phoenix, AZ 

Peter J. Goadsby, MD, PhD, FAHS, San Francisco, CA 

Rigmor H. Jensen, MD, Glostrup, Denmark 

Massimo Leone, MD, Milan, Italy 

Arne May, MD, Cologne, Germany 

Michael Moskowitz, MD, FAHS, Boston, MA 

Ana Recober, MD, Iowa City, Iowa 

Jean Schoenen, MD, PhD, Liege, Belgium 

Stephen D. Silberstein, MD, FAHS, Philadelphia, PA 

Till Sprenger, MD, Basel, Switzerland 

Key Dates 

September 10, 2012 

Registration Site Opens 

October 1, 2012 

Abstract Submission 

Site Opens 

February 1, 2013 

Deadline for Abstract 

Submission 

June 27-30, 2013 

16th Congress of 

the International 

Headache Society 

Scientific and Administrative Secretariat 

Talley Management Group, Inc. 

19 Mantua Road, Mt. Royal, NJ 08061 

Telephone: +856-423-0043 

Fax: +856-423-0082 

Email: info@ihc2013.com 

Website: www.ihc2013.com 

For more information regarding the 

16th Congress of the International 

Headache Society, please visit 

the congress website at 

www.ihc2013.com 

AMERICAN HEADACHE SOCIETY® • 19 Mantua Road, Mt Royal, NJ 08061 • IHC2013@talley.com

EHMTIC20I2 



contInued 

late BreakIng aBstracts 

lB01 Nitric oxide synthase, Calcitonin Gene-Related Peptide and inflammatory mechanisms are involved in GTN 

induced neuronal activation. 

Ramachandran, R.; Bhatt, K.; Jansen-Olesen, I.; Olesen, J. 

Glostrup Hospital, Denmark 

lB02 High frequency headache prevalence and management in primary care. A survey among general practitioners 

of the Liege area, Belgium. 

Magis, D; Schoenen, J 

Headache Research Unit - University Department of Neurology, Liege, Belgium 

lB03 Short term improvement of migraine headaches during ketogenic diet: a prospective observational study in a 

dietician clinical setting. 

Di Lorenzo, C. 1 ; Coppola, G. 2 ; Sirianni, G. 3 ; Pierelli, F. 1 

1 2 Sapienza University of Rome, Italy; G.B. Bietti Foundation-IRCCS, Dept of Neurophysiology of Vision and Neurophthalmology, 

Rome, Italy; 3Wellness and Dietary Medicine, Krom Genetics Institute, Rome, Italy 

lB04 Changes in clinical migraine picture and in headache frequency in adolescence. Three year prospective study 

Kalashyan, R 

Arabkir Medical Center, Armenia 

lB05 First demonstration of the neuroimmune link in humans using IV Endotoxin and Intradermal Capsaicin in the 

face and arm 

Rolan, P.E. 1 ; Hutchinson, M.R. 1 ; Buijs, M. 2 ; Tuke, J. 1 ; Kwok, Y.H. 1 ; Gentgall, M. 1 ; Williams, D. 3 ; Nillsen, N. 1 

1 2 3 University of Adelaide, Australia; University of Leiden, Netherlands; University of South Australia, Australia 

lB06 Post market pilot programme with single pulse transcranial magnetic stimulation (sTMS) for acute treatment 

of migraine: SpringTMS use in migraine 

Weatherall, M.W. 1 ; Bhola, R. 2 ; Giffin, N. 3 ; Goadsby, P.J. 4 

1 2 3 Princess Margaret Migraine Clinic, London, United Kingdom; eNeura Therapeutics, California, United States; Royal United 

Hospital, Bath, United Kingdom; 4UCSF, San Francisco, United States 

lB07 Role of Psychiatric disorders in association of headache and temporomandibular disorders 

Nazeri, M; Abareghi, F 

Medical Students Research Committee, Medical Sciences University, Kerman, Iran 

lB08 PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act 

centrally to achieve clinical efficacy 

Vermeersch, S.G.G. 1 ; de Hoon, J. 1 ; De Saint-Hubert, B. 1 ; Derdelinckx, I. 1 ; Serdons, K. 2 ; Bormans, G. 3 ; 

Reynders, T. 4 ; Declercq, R. 4 ; De Lepeleire, I. 4 ; Kennedy, W. 5 ; Blanchard, R. 5 ; Marcantonio, E. 5 ; Hargreaves, 

R. 6 ; Li, C.C. 6 ; Sanabria, S. 6 ; Hostetler, E. 6 ; Joshi, A. 6 ; Evelhoch, J. 6 ; Van Laere, K. 2 

1 2 Center for Clinical Pharmacology, Campus Gasthuisberg, University Hospitals Leuven (KU Leuven), Leuv, Belgium; Nuclear 

Medicine Department, UZ and KU Leuven, Belgium; 3Laboratory for Radiopharmacy, KU Leuven, Belgium; 4Merck Sharp & Dohme 

(Europe) Inc., Brussels, Belgium; 5Merck Research Laboratories, Upper Gwynedd PA, United States; 6Merck Research Laboratories, 

West Point PA, United States 

lB09 Facial spasm and headaches: Should we call it “IIH-Spasm syndrome?” 

Muzerengi, S; Moor, C; Davies, M 

University Hospital of North Staffordshire NHS trust, United Kingdom 

61

62 

EHMTIC20I2 



contInued 

lB10 In-patient/out-patient detoxification is highly effective in Medication Overuse Headache: report from a 

multicentric, multinational study 

Tassorelli, C. 1 ; Jensen, R. 2 ; Allena, M. 1 ; De Icco, R. 1 ; Katsarava, Z. 3 ; Lainez, M. 4 ; Leston, J.A. 5 ; Fadic, R. 6 ; 

Nappi, G. 1 

1 2 IRCCS Neurological Institute C. Mondino Foundation, Italy; Danish Headache Centre, Dept. of Neurology, Glostrup Hospital, 

Denmark; 3Department of Neurology, University of Essen, Germany; 4Fundación de la Comunidad Valenciana, Spain; 5Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infanzia, Argentina; 6Pontificia Universidad Catolica de Chile, Chile 

lB11 Disability caused by medication-overuse headache can be considerably reduced by detoxification. Results 

from multinational COMOESTAS study. 

Bendtsen, L. 1 ; Jensen, R. 2 ; Munksgaard, S. 2 ; Tassorelli, C. 3 ; Nappi, G. 3 ; Katsarava, Z. 4 ; Lainez, M. 5 ; Leston, 

J. 6 ; Fadic, R. 7 ; Jensen, R. 2 

1 2 Danish Headache Centre, Dept. of Neurology, Glostrup Hospital, Faculty of Health Sciences, Universit, Denmark; Danish 

Headache Center, Department of Neurology, Denmark; 3Headache Science Centre, Mondino” Foundation and Department of 

Public Health and Neurosciences, Univ, Italy; 4Department of Neurology, University of Essen, Essen, Germany; 5Fundación de la 

Comunidad Valenciana para la Investigación Biomédica, del Hospital Clínico Universit, Spain; 6Fundacion para la Lucha contra las 

Enfermedades Neurologicas de la Infanzia, Buenos Aires, Argentina; 7Pontificia Universidad Catolica de Chile, Santiago, Chile 

lB12 MRI Compatibility of the Autonomic Technologies Inc (ATI) SPG Neurostimulator – New Treatment for Cluster 

Headache (CH) 

Powell, R; Pless, E; Caparso, A 

Autonomic Technologies, Inc., United States 

lB13 Headaches in the elderly, in an out-patient population over 60 years of age. 

Venturelli, E; Rao, R; Gipponi, S; Liberini, P; Padovani, A 

Neurological Clinic Headache Center Spedali Civili University of Brescia, Italy 

lB14 Treatment of hemicrania continua by non-invasive vagus nerve stimulation in 2 patients previously treated 

with occipital nerve stimulation 

Nesbitt, A; Marin, J; Goadsby, P 

Royal Free London NHS Foundation Trust, United Kingdom 

lB15 Non-invasive vagus nerve stimulation for the treatment of cluster headache: a case series 

Nesbitt, A.D. 1 ; Marin, J.C.A. 1 ; Tomkins, E. 2 ; Ruttledge, M.H. 2 ; Goadsby, P.J. 1 

1 2 Royal Free London NHS Foundation Trust, United Kingdom; Beaumont Hospital, Dublin, Ireland 

lB16 The effect of sodium nitroprusside on cerebral haemodynamic and headache in healthy subjects. 

Guo, S. 1 ; Olesen, J. 2 ; Ashina, M. 2 ; Birk, S. 3 

1 2 Danish Headache Center, Department of Neurology, Glostrup Hospital, Denmark; Headache Center and Department of Neurology, 

Glostrup Hospital, Faculty of Health Sciences, Universi, Denmark; 3Department of Clinical Neurophysiology, Rigshospitalet,Faculty 

of Health Sciences, Universityof Cope, Denmark

EHMTIC20I2 


Migraine affects 8 million people in the UK 

Migraine is the UK’s most common long term 

neurological condition, costing an estimated 3 

billion pounds every year. For the last 40 years 

The Migraine Trust has funded vital research 

into the condition and supported sufferers and 

their families. 

The Migraine Trust provides essential, 

evidence-based information to those affected 

by migraine. We have fact sheets on migraine 

and related issues. We also run a website, an 

information and enquiry service, an advocacy 

service and practical workshops to support 

migraineurs and their families. 

Medical professionals already tell us how 

much they and their patients value the service 

we provide. 

The Migraine Trust funds research into 

migraine and disabling headache – in fact 

Together we can beat it 

we’ve invested £3 million in 130 research 

projects since we began. We also subsidise 

headache and migraine courses for nurses 

and other healthcare professionals. 

We are a charity that receives no Government 

funding in battling this widespread condition. 

We rely solely on donations. 

There are a number of ways you can help 

support our work: 

• Tell your patients about our work 

• Become part of our expert panel 

• Write a fact sheet for use 

• Speak or help at one of our workshops 

for the public 

• Take part in a challenge event such as 

running, parachuting and trekking 

• Make a donation 

Email fundraising@migrainetrust.org for more details or visit www.migrainetrust.org 

Please support our work and help us to help you and your patients. 

“Migraine is giving up its secrets to our research efforts 

and this will benefit our patients now and their children in the future” 

The Migraine Trust 

52-53 Russell Square, London, 

WC1B 4HP, United Kingdom 

Tel: 020 7631 6970 

Email: info@migrainetrust.org 

Visit: www.migrainetrust.org 

Registered Charity in England and Wales (1081300) 

and Scotland (SC042911) 

Professor Peter Goadsby, Trustee of The Migraine Trust 

63

64 

EHMTIC20I2 


exHIBItIon floor Plan 

kEY To SYmBolS: Poster Presentations Refreshments

EHMTIC20I2 


exHIBItors By 

stand numBer 

A STX-Medical 

B Autonomic Technologies Inc 

c Linde Healthcare 

D1 Lifting the Burden 

D2 American Headache Society 

E EHF/EHMTIC 2014 

F Journal of Headache and Pain / Springer 

G Electrocore Medical 

H The Menarini Group 

I Allergan Inc 

k St Jude Medical 

l Merck Sharp Dohme 

N Eurolight 

o/P eNeura 

Q The Migraine Trust 

R British Association for the Study of 

Headache (BASH) 

S National Clinical Guideline Centre (NICE) 

T International Headache Society / 

Sage Publishing 

exHIBItors In 

alPHaBetIcal order 

Allergan Inc I 

American Headache Society D2 

Autonomic Technologies Inc B 

British Association for the Study of 

Headache (BASH) 

R 

EHF/EHMTIC 2014 E 

Electrocore Medical G 

eNeura o/P 

Eurolight N 

International Headache Society / 


T 

Journal of Headache and Pain / Springer F 

Lifting the Burden D1 

Linde Healthcare c 

The Menarini Group H 

Merck Sharp Dohme l 

The Migraine Trust Q 

National Clinical Guideline Centre (NICE) S 

St Jude Medical k 

STX-Medical A 

65

66 

EHMTIC20I2 


dIrectory of sPonsors 

and exHIBItors 

PLATINUM SPONSOR 

Allergan Inc 

Stand I 

1st Floor, Marlow International 

Parkway 

Marlow 

Bucks SL7 1YL 

United Kingdom 

www.allergan.com 

Founded in 1950, Allergan, Inc., with headquarters 

in Irvine, California, is a multi-specialty health care 

company that discovers, develops and commercializes 

innovative pharmaceuticals, biologics and medical 

devices that enable people to live life to its greatest 

potential – to see more clearly, move more freely, 

express themselves more fully. The Company employs 

approximately 8,000 people worldwide and operates 

state-of-the-art R&D facilities and world-class 

manufacturing plants. In addition to its discovery-todevelopment 

research organization, Allergan has global 

marketing and sales capabilities with a presence in 

more than 100 countries. 

American Headache Society 

Stand D2 

19 Mantua Road 

Mt Royal, NJ 

08061 

USA 

Tel: +1 856 423 0043 

Email: AHSHQ@talley.com 

www.AmericanHeadacheSociety.org 

The American Headache Society®, is the professional 

organization for those interested in the study and 

management of headache and face pain. The Society’s 

objectives are to promote the exchange of information 

and ideas concerning the causes and treatments of 

headache and related painful disorders. Educating 

physicians, health professionals, the public and 

encouraging scientific research are the primary 

functions of this Society. The journal Headache is the 

official publication. Recently the Society founded the 

American Migraine Foundation to support innovative 

research that will lead to improvement in the lives who 

suffer from migraine and other disabling headaches. 

Autonomic Technologies Inc 

Stand B 

3698 Haven Ave, Suite C 

Redwood City 

CA 94063 

USA 

Tel No: +1 650 216 6107 

Fax No: +1 650 216 6106 

Email: info@ati-spg.com 

www.ati-spg.com 

Autonomic Technologies, Inc. (ATI) has pioneered a 

miniaturized implantable neurostimulation device 

that stimulates the sphenopalatine ganglion (SPG) to 

provide relief from the debilitating pain and suffering 

caused by severe headaches. The ATI Neurostimulation 

System is CE marked to relieve the acute pain of 

cluster headache and has been associated with a 

reduction in the number of cluster headaches. The 

implanted neurostimulator’s service life is not limited 

by battery depletion. It is the only neurostimulator with 

MR Conditional labeling for whole-body MRI scans. 

The ATI Neurostimulation System is currently being 

studied for the treatment of migraine. 

British Association for the Study of Headache (BASH) 

Stand R 

Dept of Neurology 

Hull Royal Infirmary 

Anlaby Road, Hull HU3 2JZ 


Tel: +44 (0) 207 631 6979 

Email: info@bash.org.uk 

www.bash.org.uk 

BASH is a national society for healthcare professionals 

with interest in headache. We are a group of both 

primary and secondary care doctors, nurses and 

therapists working with headache patients. 

We are committed to promoting headache education 

among healthcare professionals and the general public. 

• We organise UK wide educational programmes for 

professionals and the general public 

• We collaborate with key patient charities and other 

headache organisations 

• We represent the views of the headache community 

• We are involved in lobbying for headache services 

in the UK 

• We provide headache treatment guidelines 

Join us: 

Membership is open to all health care professionals

EHMTIC20I2 


with an interest in headache. 

Contact: 

Professional enquiries: info@bash.org.uk 

Membership enquiries: membership@bash.org.uk 

Visit: www.bash.org.uk 

EHF (European Headache Federation) 

Stand E 

1-3 rue Chantepoulet 

P.O. Box 1726 

1211, Geneva 

Switzerland 

Tel: +41 22 906 91 69 

Fax: +41 22 732 2607 

Email: irah@kenes.com 

www.ehf-org.org 

Since 1992, the European Headache Federation 

(EHF) has sought to improve life for those affected by 

headache in Europe. 

Within its federal structure, EHF supports national 

headache societies with a specific focus on Eastern 

European countries. 

EHF Main Activities: 

• Biennial Congresses – Next: EHMTIC 2012 – 

London, UK 

• Cooperation on peer-reviewed The Journal of 

Headache and Pain 

• European Headache Schools including the new Video 

• Teleconference format 

• Teaching courses for GPs and non-physicians 

• Awards, scholarships 

• Guideline for treatment of headache 

• Bi-monthly Newsletter 

Join us to review the most recent developments in 

headache research & management! 

Electrocore Medical 

Stand G 

51 Gibraltar Drive, Suite 5C 

Morris Plains, NJ 

07950 

USA 

Tel: +1 617 620 8570 

Email: Jennifer.Berman@electrocoremedical.com 

www.electrocoremedical.com 

The GammCore therapy is a non-invasive vagus nerve 

stimulator that produces a mild electrical signal that 

is transmitted to the vagus nerve through the skin 

to treat and/or prevent Migraine, Cluster Headache, 

and Medication overuse headache. For many years, 

vagus nerve stimulation has been used to treat 

various disorders such as epilepsy and depression, 

in thousands of patients. The GammaCore device 

provides a safe and effective non-invasive treatment for 

migraines, cluster and some other headaches, without 

the side effects associated with drugs. 

GOLD SPONSOR 

eNeura Therapeutics 

Stands O & P 

240 North Wolfe Road 

Sunnyvale 

CA 94085 

USA 

Tel: + 1 408 245 6400 

Email: customercare@eneura.com 

www.eneura.com 

eNeura Therapeutics, a privately held medical 

technology company, is pioneering the use of portable, 

non-invasive Transcranial Magnetic Stimulation 

(TMS) devices for treatment of migraine. Prescribed 

by physicians but designed for patient use, The 

SpringTMS Total Migraine System is the first truly 

portable, convenient TMS product that will allow 

migraine patients to administer treatment as needed – 

at home, in the office or on the go. 

Eurolight 

Stand N 

1 A-B rue Thomas Edison 

L-1445 Strassen 

Luxembourg 

L1445 

Tel: + 41 7921112252 

Email: Colette.andree@crp-sante.lu 

www.crp-sante.lu www.eurolight-online.eu 

The Public Research Centre for Health(CRP-Santé), is 

the leading public organisation for basic, pre-clinical 

and clinical research in life sciences in Luxembourg. 

CRP-Santé has been founded in 1988 based on the first 

Luxembourg law on research and development (R&D). 

CRP-Santé’s mission is to deliver scientific, economic 

and societal value for Luxembourg by performing 

research, studies and developments in the fields of 

clinically-oriented biomedical research and public 

health. CRP-Santé’s activities lead to the generation of 

new knowledge in disease mechanisms, epidemiology, 

diagnostics and treatments of human diseases, and 

67

68 

EHMTIC20I2 




contInued 

they improve the understanding of health determinants 

and of the financial structures of health care.CRP-Santé 

aims at translating knowledge into clinical applications 

impacting on healthcare while shaping personalized 

medicine in close collaboration with hospitals, health 

care. It is the first supplier of public health information 

in Luxembourg, enabling public authorities to make 

decisions based on scientific data and to communicate 

validated data to international institutions. It is a 

reliable and active partner for training and higher 

education in close collaboration with national and 

international universities. CRP-Santé has 250 scientific 

and 50 support staff, which performed in 2010 more 

than 142 research projects and published 210 peerreviewed 

papers. 

International Headache Society / Sage Publishing 

Stand T 

41 Welbeck Street 

London W1G 8EA 


Registered Charity no. 1042574 

Tel: +44 1629 733406 

Fax: +44 207 504 8788 

www.i-h-s.org 

Advancing headache science, education and 

management and promoting headache awareness 

worldwide IHS is the world’s leading organisation for 

all whose professional commitment, whatever their 

discipline, is to helping people whose lives are affected 

by headache disorders. 

As a professional organisation we work with others for 

the benefit of people affected by headache disorders. 

IHS members have access to a wide range of benefits 

such as (a) Cephalalgia (b) online access to The 

Neuroscientist (d) access to the online learning centre 

(e) reduced registration fee to the IHC (f) eligibility to 

apply for awards(g) early access various publications. 

To learn more visit us at www.i-h-s.org 


SAGE is a leading international publisher of journals, 

books, and electronic media for academic, educational, 

and professional markets. Since 1965, SAGE has 

helped inform and educate a global community of 

scholars, practitioners, researchers, and students 

spanning a wide range of subject areas including 

business, humanities, social sciences, and science, 

technology and medicine. An independent company, 

SAGE has principal offices in Los Angeles, London, 

New Delhi, Singapore and Washington DC. 

www.sagepub.co.uk 

Journal of Headache and Pain / Springer 

Stand F 

Via Decembrio, 28 

20137 – Milano 

Italy 

Tel: +39 02 542597-1 

Fax: +39 02 55193360 

www.springer.com 

Our business is publishing. Knowledge, information 

and quality – these are the three things that shape 

Springer Science+Business Media’s business activities. 

We develop, manage and disseminate knowledge – 

through books, journals and the Internet. We work 

with the world’s best academics and authors in longstanding 

loyal partnerships based on mutual trust and 

we are always open to new input. 

We aim to offer excellence – more than 150 Nobel 

prize-winners have published with Springer to the 

present date. Many of our publications are considered 

authoritative works in their field, read by academics 

and students, used by libraries and universities, 

academic professionals and practitioners in various 

branches of industry. 

Lifting the Burden 

Stand D1 

41 Welbeck Street 

London W1 8EA 


Tel: +44 (0) 7768 547440 

Email: u.schultz@l-t-b.org 

www.l-t-b.org 

Lifting The Burden is a charitable company in Official 

Relations with the World Health Organization, whose 

purpose is to support and direct the Global Campaign 

against Headache, a programme of collaborative 

activity with WHO, academic institutions, international 

headache NGOs and individuals for the benefit of 

people affected by headache disorders in all countries 

of the world.

EHMTIC20I2 


SPONSOR 

Linde Healthcare 

Stand C 

Seitnerstrasse 70 

DE-82049 Pullach 

Germany 

www.linde-healthcare.com 

Linde Healthcare is dedicated to providing products, 

therapies and services to hospitals, patients, clinics, 

nursing facilities and emergency management services. 

Present in 70 countries around the world, we have 

established a solid foundation as the medical gas and 

clinical care specialist. We work to ensure our solutions 

are always delivered and serviced to the highest 

possible standards of quality and security. A true 

healthcare partner, we combine a unique knowledge 

of healthcare realities with continuous research and 

development. 

SILVER SPONSOR 

The Menarini Group 

Stand H 

Via Sette Santi 3 

50131 Florence 

Italy 

Tel: +39 055 56801 

Fax: +39 055 5680484 

www.menarini.com 

A.Menarini is the largest Italian pharmaceutical group 

and it ranks the world’s number 35 and the Europe’s 

number 19. Menarini is present in more than 100 

countries worldwide. Menarini is investing 10% of 

its turnover in R&D, mainly in cardiovascular field, 

oncology, pain-inflammation and asthma. 

Frovatriptan is a newly introduced anti-migraine drug, 

which stands out for its high potency at 5-HT1B 

receptors and its long half life. Frovatriptan’s long 

half life provides sustained relief and may contribute 

together with the drug’s high potency at 5-HT1B 

receptors to its low rate of 24-hours headache 

recurrence, thus avoiding the need for a repeat dose. 

The Migraine Trust 

Stand q 

52-53 Russell Square 

London WC1B 4HP 


Tel: +44 (0) 20 7631 6970 

Registered Charity in England and Wales (1081300) 

and Scotland (SC042911) 

Tel: +44 (0) 20 7436 1336 

Email: info@migrainetrust.org. 

www.migrainetrust.org 

Migraine is the UK’s most common long term 

neurological condition, costing an estimated 3 billion 

pounds every year. For the last 40 years The Migraine 

Trust has funded vital research into the condition and 

supported sufferers and their families. The Migraine 

Trust provides essential, evidence-based information 

to those affected by migraine. We have fact sheets on 

migraine and related issues. We also run a website, an 

information and enquiry service, an advocacy service 

and practical workshops to support migraineurs and 

their families. Medical professionals already tell us 

how much they and their patients value the service 

we provide. The Migraine Trust funds research into 

migraine and disabling headache – in fact we’ve 

invested £3 million in 130 research projects since 

we began. We also subsidise headache and migraine 

courses for nurses and other healthcare professionals. 

We are a charity that receives no Government funding 

in battling this widespread condition. We rely solely 

on donations. 

There are a number of ways you can help support 

our work: 

• Tell your patients about our work 

• Become part of our expert panel 

• Write a fact sheet for us 

• Speak or help at one of our workshops for the public 

• Take part in challenging events such as running, 

parachuting and trekking 

• Make a donation 

Email fundraising@migrainetrust.org for more details 

or visit www.migrainetrust.org 

Please support our work and help us to help you and 

your patients. 

National Clinical Guideline Centre (NICE) 

Stand S 

Royal College of Physicians 

11 St Andrews Place 

Regents Park 

London NW1 4LE 


Contact Name: Serena Carville 

Tel: 020 3075 1433 

Fax: 020 7631 5097 

Email: serenacarville@rcplondon.ac.uk 

www.ncgc.ac.uk 

69

70 

EHMTIC20I2 




contInued 

The NCGC was formed in April 2009 following the 

merger of the National Collaborating Centres for Acute 

Care, Chronic Conditions, Nursing and Supportive and 

Primary Care. We are hosted by the Royal College of 

Physicians and have governance partnerships with the 

Royal College of Surgeons of England, Royal College 

of General Practitioners, Royal College of Nursing and 

Royal College of Physicians. 

We are commissioned by the National Institute of 

Health and Clinical Excellence (NICE) to develop and 

produce clinical guidelines on a broad range of clinical 

and care related topics. We have 20 guidelines in 

development at any one time, making us one of the 

largest clinical guideline centres in the world. 

STX-Medical 

Stand A 

Science Park Liege 

Chasseurs Ardennais 4 

B 4031 

Angleur 

Belgium 

Tel: +32 43676722 

Fax: +32 43676702 

www.stx-med.com 

STX-Med Company develops practical innovations 

for use on humans in the field of electronics and 

bio-electronics. It has developed an expertise in 

external recording (biofeedback) and producing 

(neurostimulation) signals at the cranial level. The 

products developed by STX-Med are for external 

occipital and/or trigeminal neurostimulation as well 

as biofeedback. All STX-Med’s products use wireless 

technology. They are fully programmable by the 

neurologist via software and a computer interface. All 

products register the patient compliance in order to 

be control precisely and easily by the neurologist.

BOTOX ® in chronic migraine * 

If chronic migraine is the only thing she can plan for, change her plans 

*Headaches on at least 15 days per month of which at least 8 days are with migraine. 

Prescribing information 

BOTOX ® (botulinum toxin type A) 

Chronic Migraine Abbreviated Prescribing Information 

Presentation: Botulinum toxin type A (from clostridium botulinum), 50 or 100 or 200 Allergan Units/vial. Indications: Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 

days are with migraine). Dosage and Administration: See Summary of Product Characteristics for full information. Reconstitute with sterile unpreserved normal saline (0.9% sodium chloride for injection). Doses recommended for BOTOX ® 

are not interchangeable with other preparations of botulinum toxin. Inject using 30 gauge, 0.5 inch needle, or 1 inch needle for thicker muscles in neck region if required. Inject 0.1ml (5U) intramuscularly to 31 (up to 39) injection sites, divided 

across seven specific head/neck muscle areas including frontalis, corrugator, procerus, temporalis, trapezius and cervical paraspinal muscles. Inject bilaterally, with the exception of procerus. Total dose 155U-195U. Contra-indications: Known 

hypersensitivity to any constituent. Pregnancy or lactation. Presence of infection at proposed injection site(s). Warnings/Precautions: Relevant anatomy and changes due to prior surgical procedures must be understood prior to administration. 

Adrenaline and other anti-anaphylactic measures should be available. Reports of side effects related to spread of toxin distant from injection site, sometimes resulting in death. Caution in patients with underlying neurological disorder and history of 

dysphagia and aspiration. Patients should seek medical help if swallowing, speech or respiratory disorders arise. Clinical fluctuations may occur during repeated use. Too frequent or excessive dosing can lead to antibody formation and treatment 

resistance. The previously sedentary patient should resume activities gradually. Caution in the presence of inflammation at injection site(s) or when excessive weakness/atrophy is present in target muscle. Caution when used for treatment 

of patients with peripheral motor neuropathic disease. Use with extreme caution and close supervision in patients with defective neuromuscular transmission (myasthenia gravis, Eaton Lambert Syndrome). Contains human serum albumin. 

Procedure related injury could occur. Efficacy has not been shown in prophylaxis of episodic migraine (headaches

EHMTIC20I2 



EHMTIC Limited - registered charity no 1121734

sunday 23 sEpTEMbEr - ehmtic 2012

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?